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1 Introduction 
1.1 Traditional medicine and medicinal plants 
Plant-based systems play an essential role in health care. Medicinal plants have a long 
tradition in various cultures all around the world. Although modern medicine is well 
developed and accepted in most parts of the world, there is a high demand for herbal 
medicine and remedies.  
Folk medicine or traditional medicine used to prevent or cure diseases has a long history and 
is based on acquired knowledge developed over generations. The World Health Organization 
(WHO) defined traditional medicines as “the sum total of the knowledge, skills, and practices 
based on the theories, beliefs, and experiences indigenous to different cultures, whether 
explicable or not, used in the maintenance of health as well as in the prevention, diagnosis, 
improvement or treatment of physical and mental illness.” (WHO, 2010). In traditional 
medicine, herbal substances and preparations thereof are frequently applied. The European 
Medicines Agency established the Committee on Herbal Medicinal Products (HMPC). Its task 
is to assist in the harmonization of procedures and provisions concerning herbal medicinal 
products within the European Union and further integrating herbal medicinal products in the 
European regulatory framework.  
According to the European directive 2001/83/EC as amended (including directive 
2004/24/EC), herbal substances include mainly whole, fragmented or cut plants, plant parts, 
fungi and lichen in an unprocessed, usually dried, form. Subsequently, herbal preparations 
are obtained by subjecting herbal substances to treatments such as extraction, distillation, 
expression, fractionation, purification, concentration or fermentation. 
The European Directorate for the Quality of Medicines & HealthCare (EDQM), responsible 
for the elaboration of the European Pharmacopeia, defined the term herbal drug and herbal 
drug preparation synonymous to herbal substance and herbal preparation.  
In Germany, about 2,000 herbal medicinal products are registered or approved at the 
Federal Institute for Drugs and Medical Devices (BfArM). Plant parts or plant material in the 
crude or processed state are regarded as active substance. Herbal substances or their 
preparations are administered as tea, extracts, tablets, capsules, solutions, juice, 
suppository, salves or cream. 
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1.2 Quality control and characterization of herbal substances and 
preparations thereof 
The composition of phytochemical constituents within an herbal substance depends on many 
factors like the plant parts used, genetic variation, collection period, makeup of soil, climatic 
conditions, drying and storing methods and geographical location (Bandaranayake W., 2006; 
Bauer R., 1998). 
For safe use the quality of herbal substances is a significant characteristic as it determines 
the biological activities. The quality of herbal medicinal products is assured by a defined 
manufacturing process and additionally subjected to quality control. Medicinal plants 
comprise a mixture of various phytochemical constituents; thus, the appropriate quality 
control is challenging as a plant may comprise up to 200,000 metabolites (Fiehn O., 2001).  
The quality criteria for herbal substances are based on a clear definition of the raw material 
documented in pharmacopeial monographs. When assessing the quality, sensory features, 
moisture, ash, physical constants, solvent residues and adulterations have to be checked to 
prove identity and purity. Additionally, herbal substances are tested for contaminations, such 
as heavy metals, pesticide residues, aflatoxins, and radioactivity. The identity is frequently 
analyzed by fingerprint methods like thin-layer chromatography (TLC) and the constant 
composition is ensured by the determination of selected marker compounds, e. g. using high 
performance liquid chromatography (HPLC) and gas chromatography (GC).  
1.3 Omics-techniques for the comprehensive characterization of herbal 
substances and preparations thereof 
1.3.1 Omics-techniques and systems biology 
The suffix “omics” is used for high-throughput technologies frequently used in various 
disciplines. It describes the analysis of the totality of the field of science. In recent 
publications omics-technologies are used in a broader sense but it still implies the 
investigation of a high number of samples.  
The application of these techniques was achieved due to the IT-based data evaluation using 
systems biology. This discipline has emerged since the third millennium. It is an 
interdisciplinary field of science and combines knowledge and tools from biology, computer 
sciences, medicine, physics, chemistry and engineering (Medina M., 2013).  
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Various classes of biological compounds, from genes through mRNA to proteins and 
metabolites, can be analyzed by the respective omic approaches, namely, genomics, 
transcriptomics, proteomics, or metabolomics (fig. 1).  
 
Fig. 1: Scheme of the ‘omic’ organization (adopted from Buszewski B., 2009). The 
flow of information is from genes to transcripts to proteins to function.  
The term genomics was first coined by Thomas Roderick, meaning the study and 
comparison of genomes across species (Kuska B., 1998).  
The transcriptome comprises the set of all RNAs (mRNA, tRNA, rRNA and other non-coding 
RNA) present in a single cell or organism. Techniques investigating the transcriptome usually 
investigate the gene expression level; hence, the information is passed from DNA via 
messenger RNA (mRNA). 
First Marc Wilkins coined the term proteomics, to describe an entire organism’s protein 
complement expressed by a genome (Yadav S., 2007). In contrast to the genome, the 
transcriptome and the proteome are highly dynamic. The study of the proteome is rather 
complex. A single gene can be processed to result in several different mRNAs or proteins. 
Accordingly, metabolomics is a scientific field investigating small molecules within a 
biological sample. Variations in metabolite composition may be taken as the downstream 
result of changes in gene expression and protein translation; therefore, it is expected to be 
amplified relative to changes in the transcriptome and proteome (Silvestri E., 2011). 
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1.3.2 Analysis of herbal preparations by metabolomic fingerprinting 
The term metabolome is defined as the complete set of small-molecule metabolites to be 
found within a biological sample, such as a single organism (Oliver S., 1998). The highly 
dynamic metabolome includes small molecule metabolites essential for the maintenance and 
growth of a cell or organism and comprises classes of compounds related to hormones, 
metabolic intermediates, signaling molecules and secondary metabolites (Sumner L., 2003). 
Metabolomic techniques are very useful for studying plant biochemistry, chemotaxonomy, 
ecology, pharmacology and quality control of herbal substances (van der Kooy F., 2009).  
The most common methods in the investigation of the metabolome are nuclear magnetic 
resonance spectroscopy (NMR), chromatographic methods and mass spectrometry. 
Furthermore, hyphenated techniques like LC/MS or LC/NMR are likely to have an increased 
impact (Ulrich-Merzenich G., 2007; Verpoorte R., 2005).  
For the investigation of the metabolome several applications are known (Fiehn O., 2000; 
Fiehn O., 2002). Metabolic profiling aims at the qualitative and quantitative analysis of a 
group of related compounds. Methods related to metabolomics aim at the qualitative and 
quantitative analysis of all metabolites within one organism. Metabolic or metabolomic 
fingerprinting aims at measuring a fingerprint of metabolites within an organism. This 
technique is applied without identification of all compounds, but rather used for sample 
classification by rapid global analysis (Ulrich-Merzenich G., 2007; Verpoorte R., 2005). 
In a previous PhD project in our group, a metabolomic fingerprint method was successfully 
established. Crude herbal preparations were investigated by 1H-NMR analysis in combination 
with principal component analysis (PCA) to evaluate 1H-NMR data (Daniel C., 2009). PCA is 
a mathematical procedure. It is an unbiased technique and useful in the reduction of 
dimensionality of data obtained by 1H-NMR analysis. In addition, PCA is useful in pattern 
recognition and applied to classify data. The score plot is a summary of the relationship 
among the samples. The loading plot summarizes the variability and is an additional tool to 
interpret the patterns displayed in the score plot.  
1.3.3 Investigation of gene expression profiling 
Genes are defined as the smallest unit of DNA or RNA needed for the final product of gene 
expression. The origin of gene expression in eukaryotes, prokaryotes and some viruses is 
DNA, which is transcribed into RNA. The final products of gene expression are proteins.  
The regulation of genes is essential for all organisms and involved in processes related to 
cellular differentiation and morphogenesis. Furthermore, genes are regulated in response to 
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an environmental stimulus, which leads to an increase or decrease of the production of 
functional gene products (RNA or protein).  
The transcriptome is dynamic and continuously responding to physiological and 
environmental conditions. According to the database NCBI, the human transcriptome 
comprises 20,724 protein-coding genes (www.ncbi.nlm.nih.gov/gene; 22. 3. 2014). The 
number of non-protein-coding genes bridges the total number of about 48,000 entries plus 
isoforms and transcript variants. Approximately 50% of the genes are non-coding for a 
protein. But this does not implicate that such RNAs do not contain information nor have any 
function. Non-coding RNAs seem to be particularly abundant in roles that require highly 
specific nucleic acid recognition without complex catalysis, such as in directing post-
transcriptional regulation of gene expression or in guiding RNA modifications (Eddy S., 
2001).  
Microarray technology: 
There are several techniques available to analyze gene expression, like serial analysis of 
gene expression (SAGE), northern blot, quantitative reverse transcription PCR (qRT-PCR) 
and expressed sequence tags (ESTs) (Malone J., 2011).  
Moreover, high-throughput systems are available, such as next-generation sequencing or 
microarray analysis. The term microarray itself, also known as “biochip”, simply describes 
that a high number of molecules are arranged on an extremely small space, commonly on a 
glass slide (fig. 2) (Mülhardt C., 2013; Ulrich-Merzenich G., 2007). 
 
 
Fig. 2: A hybridized microarray slide using 
one color labeling. The Agilent 8x60K 
microarray (Whole Genome Gene Expression 
Microarrays v2, Agilent Technologies, 8x60K) 
has eight arrays per slide, each with 50,599 
features. 
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The hybridisation-based DNA microarray technology has been implemented into various 
fields, due to low costs, ease in use and evaluation and optimized quality control (Brazma A., 
2001). In 1987, one of the first manuscripts was published that described microarray 
experiments including the simultaneous investigation of 96 sequences (Kulesh D., 1987). 
Nowadays, gene expressions of thousands of genes up to the whole transcriptome are 
simultaneously analyzed. 
In the early stage, there was much concern about the quality of microarray results. Recent 
investigations pointed out that an appropriate study design, considering cell or tissue type 
with adequate sample number, and sample storage are important factors for good quality. It 
was shown that experimental variation has a major impact on the reliability of gene 
expression results. Regarding quality control, sample preparation, RNA extraction, labeling, 
hybridization and chip assignment have to be performed according to a standardized 
procedure (McHale C., 2013). Furthermore, interlaboratory tests, comparisons and 
knowledge in statistical data evaluation are important to obtain biological relevant data 
(Bammler T., 2005; Irizarry R., 2005). Quality control practices were designed to overcome 
biases and experimental variability. The MicroArray Quality Control consortium (MAQC) 
developed guidelines and provided quality control standards, which are widely accepted by 
the scientific community (Shi L., 2006; Shi L., 2010).  
The application of DNA microarray technology is diverse. Researchers and the 
pharmaceutical industry use microarray technique in diagnostics, pharmacogenomics, and 
epigenetic studies (Heller M.J., 2002). Gene expression profiling is used to discover the 
mechanism of action, toxicity or early effects of cells, risk assessment and the discovery of 
biomarkers predictive for certain diseases (Cui Y., 2010; Currie R., 2012; McHale C., 2013). 
In herbal drug research the applications of DNA microarrays are related to 
pharmacodynamics, discovery of biomarkers, toxicogenomics as well as the elucidation of 
the molecular mechanism of action and the discovery of new drugs (Chavan P., 2006). 
Further, this technique is used for the prediction of safety, assessment of side effects (Lord 
P., 2006; Ulrich-Merzenich G., 2012) and the correct botanical identification and 
authentication of crude plant materials as part of standardization and quality control (Chavan 
P., 2006).  
1.4 Identification of herbal substances by DNA markers 
Macroscopic and microscopic tests and thin-layer chromatography are frequently employed 
to ensure identity and purity by phenotypic characteristics of herbal substances. 
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Furthermore, herbal substances can be identified by genotypic characteristics by the use of 
molecular markers. 
A molecular marker is a particular sequence of DNA showing variability between different 
species in the nucleic acid sequence. The genotype is phenotypically neutral and mostly 
unaffected by environmental conditions or prolonged storage of the herbal substance. The 
use of molecular markers is independent of the state of grinding of the herbal substance 
(Kersten T., 2013).  
However, subsequent treatment and processing of herbal substances have shown limitations 
for the use of molecular markers. DNA is often degraded during manufacturing of finished 
herbal medicinal products. Additionally, the quality of DNA is frequently affected during 
processing of herbal medicine derived from traditional Chinese medicine (Daniel C., 2009).  
For reliable identification of herbal substances, the appropriate marker sequences have to be 
selected. They must be conserved within a species and are highly variable between closely 
related species. The length of the marker region is an important characteristic, since the 
amount of information has to be reasonable for proper identification. However, the 
amplification of shorter fragments is more feasible, particularly from processed herbal 
substances. Furthermore, for the reliable identification valid reference data are highly 
important (Erickson D., 2008).  
1.4.1 Identification of herbal substances by locus-specific DNA markers 
For DNA barcoding of medicinal plants several marker regions are known. In plants, 
chloroplasts, mitochondria and the nucleus have their own genetic information.  
Several marker sequences located in the DNA of the chloroplast (matK, rbcL, psbA, trnH) 
have successfully been applied for the identification of plants (Gao T., 2011; Liu Y., 2012; Liu 
Y., 2013; Saarela J., 2013).  
Cytochrome oxidase 1 (Cox1) is a marker sequence located in the mitochondria and 
frequently used for barcoding investigations in animals. For the identification of plants it was 
shown to be insufficient as the variability of the mitochondrial DNA is too low (Hebert P., 
2003; Kerr K., 2007). 
The internal transcribed spacer region (ITS) and the closely related external transcribed 
spacer region (ETS) are located in the region of the 18S-5.8S-26S nuclear ribosomal cistron 
(fig. 3).  
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Fig. 3: Graphic scheme of a part of the nuclear ribosomal cistron. The arrows indicate the 
binding site of the universal plant specific primers (modified from Kersten T., 2013). ETS: 
external transcribed spacer, ITS: internal transcribed spacer, NTS: non-transcribed spacer. 
ITS and ETS refer to segments of non-functional RNA involved in the maturation of RNA. In 
a previous research project in our group, universal plant specific deoxyoligonucleotides were 
established to investigate the potential to identify herbal substances (Kersten T., 2013). 
1.5 Herbal substances characterized in the present study 
Within the study presented, three different herbal substances were characterized by their 
metabolomic profile and functional activity.  
1.5.1 Chelidonium majus L. 
The dried aerial parts of Chelidonium majus L. (Papaveraceae) 
(fig. 4) are used as herbal substance. From the aerial parts and 
the roots more than twenty isoquinoline alkaloids like chelidonine, 
protopine, coptisine, berberine, stylopine and sanguinarine have 
been isolated (Colombo M., 1996).  
Chelidonii herba is monographed in the European Pharmacopeia. 
According to the monograph (8.0, 07/2012:1861), the herbal 
substance is specified to contain not less than 0.6% of alkaloids, 
expressed as chelidonine, in relation to the dry weight of the 
herbal substance.  
The German Commission E indicated Chelidonii herba for the use in spastic discomfort of 
bile ducts and gastrointestinal tract. Several reports describe cases related to liver toxicity 
(De Smet P., 2002; Stickel F., 2003; Strahl S., 1998; Teschke R., 2012). Thus, since 2008, 
Chelidonii herba has been affected by a graduated scheme in Germany stating a negative 
benefit-risk profile (Bundesinstitut für Arzneimittel und Medizinprodukte, 2009). Preparations 
containing Chelidonii herba with a daily dosage of more than 2.5 mg/day are excluded from 
the market. The assessment of the HMPC for Chelidonii herba considered a negative 
 
Fig. 4: Chelidonii herba. 
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benefit-risk profile for the oral use not excluding product-specific applications (Committee on 
Herbal Medicinal Products, 2011).  
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1.5.2 Actaea racemosa L. 
The dried rhizome of Actaea racemosa L. (syn. Cimicifuga 
racemosa (L.) Nutt., Ranunculacea) is used as herbal substance 
(fig. 5). 
Herbal preparations of Cimicifugae racemosae rhizoma contain a 
complex mixture of triterpene glycosides, the major constituents 
are actein, 23-epi-26-deoxyactein (syn. 27-deoxyactein), 
acetylshengmanol-3-O-xyloside, cimigenol 3-O-arabinoside and 
cimigenol 3-O-xyloside (Bedir E., 2000; Chen S., 2002c; He K., 
2006; Shao Y., 2000; Watanabe K., 2002).  
Cimicifugae racemosae rhizoma is included in the European 
Pharmacopeia (8.0, 07/2012:/2069). According to the 
monograph, the content of triterpenes glycosides is specified to a 
content of at least 1.0%. 
Furthermore, the herbal substance is monographed in the American Herbal Pharmacopeia 
(USP35-NF30S1) and in the Chinese Pharmacopeia 2010. The monographs of the different 
pharmacopeias differ in the plant source used. In the Chinese Pharmacopeia, C. heracleifolia 
Kom., C. dahurica (Turcz.) Maxim. and C. foetida L. are used species, while in the European 
Pharmacopeia and American Herbal Pharmacopeia A. racemosa (L.) is described as the 
plant source. In the European Pharmacopeia monograph of Cimicifugae racemosae rhizoma, 
a TLC method was developed to detect contaminations with closely related species, such as 
C. americana Michx., C. foetida, C. dahurica and C. heracleifolia.  
In the monograph of the Commission E, published in 1989, Cimicifugae racemosae rhizoma 
was indicated for premenstrual and menopausal disorders. The HMPC reassessed this 
herbal substance in 2010 (Committee on Herbal Medicinal Products, 2010b). According to 
the HMPC monograph on this herbal substance, Cimicifugae racemosae rhizoma is 
considered to be safe under appropriate labelling (Committee on Herbal Medicinal Products, 
2010a). Its use is limited to postmenopausal women with a benefit of the herbal substance 
used for the relief of menopausal complaints such as hot flushes and profuse sweating 
(Committee on Herbal Medicinal Products, 2010a).  
Questions have been raised about the safety of Cimicifugae racemosae rhizoma. Cases of 
liver toxicity in patients taking this herbal substance were reported, subsequent evaluation 
found some products to be adulterated with other related herbal species (Patel N. and 
Derkits R., 2007; Gardiner P., 2008; Joy D., 2008; Pierrard S. 2009; Vannacci A., 2009; 
Painter D., 2010). In Germany, a graduated scheme has been effective since 2009, directing 
 
Fig. 5: Cimicifugae 
racemosae rhizoma. 
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warnings and precautions regarding the risk of hepatotoxicity and the consumption of 
Cimicifuga containing medicines (Bundesinstitut für Arzneimittel und Medizinprodukte, 2009). 
1.5.3 Silybum marianum (L.) Gaertn. 
The mature fruits of Silybum marianum (L.) Gaertn. (Asteraceae) 
(fig. 6) and preparations thereof have been marketed for several 
decades. 
The group of constituents described to be responsible for the 
pharmacological activity is a mixture called silymarin. Silymarin 
comprises polyphenolic molecules including the flavonolignans 
silibinin, isosilibinin, silidianin, silichristin and isosilochristin. In 
Silybi mariani fructus, silymarin is identified to a content of 1.5-3% 
(Halbach G., 1971). 
The European Pharmacopeia contains a monograph of Silybi mariani fructus (8.0, 
01/2014:1860). According to the monograph, a content of at least 1.5% of silymarin, 
expressed as silybin, is specified for the herbal substance.  
Silybi mariani fructus is traditionally used. The Commission E described the use in cases of 
toxic liver damage, liver diseases and supportive treatment of chronic inflammatory liver 
diseases. In Germany, silymarin is approved for the treatment of Amanita phalloides 
poisoning administered as an antidote in large doses.  
 
Fig. 6: Silybi mariani 
fructus. 
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2 Scope of the present study 
The present thesis was performed in cooperation of the Institute of Pharmaceutical Biology at 
the University of Bonn and the BfArM. The project focused on the characterization of herbal 
substances and preparations thereof.  
For quality control and characterization of herbal substances and their preparations, currently 
applied standard methods have shown limitations. Hence, the potential of recently emerging 
new methodologies was investigated to comprehensively characterize herbal substances 
and their preparations. In the last decades, progress was achieved in molecular and 
analytical methods. Therefore, a metabolomics-based approach together with gene 
expression profiling was used to characterize herbal substances and preparations thereof.  
The focus of the project was to bridge data about functional characteristics obtained by gene 
expression profiling and the metabolomic profile of herbal preparations. Human liver cells 
exposed to herbal preparations were investigated by microarrays with a focus on a specific 
gene expression fingerprint and systems biological data evaluation. In a previous research 
project, it was shown that a metabolomics-based approach is an appropriate method to 
characterize the chemical composition of herbal preparations. Therefore, it was used for 
phytochemical profiling of samples in addition to standard methods described in the 
European Pharmacopeia. The models investigated were chosen from medicinal plants for 
which either safety concerns associated with liver toxicity were reported (C. majus and A. 
racemosa) or for which therapeutic use associated with liver diseases were reported (S. 
marianum). 
The proof of herbal identity is mandatory for quality control of herbal substances and their 
preparations. Hence, in a second approach, a combination of a PCR-based method and the 
metabolomics-based approach was used to identify and classify herbal substances and 
herbal preparations. In this subproject, the potential of the combination of both methods was 
evaluated more in detail using herbal substances from Asian therapeutic systems. 
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3 Combining metabolomic analysis and microarray gene 
expression analysis in the characterization of the medicinal 
plant Chelidonium majus L.  
3.1 Abstract  
Background and objective: Even though herbal medicines have played an important role in 
disease management and health for many centuries, their present frequent use is challenged 
by the necessity to determine their complex composition and their multitarget mode of action. 
In the present study, modern methods were investigated towards their potential in the 
characterization of herbal substances. As a model the herbal substance Chelidonii herba 
was used, for which several reports on liver toxicities exist. Extracts of Chelidonii herba with 
different solvents were chemically analyzed and functionally characterized by experiments 
with HepG2 liver cells. 
Methods: Chelidonii herba was extracted with four solvents of different polarity 
(dichloromethane, water, ethanol, and ethanol 50% (V/V); four replicates each). The different 
extracts were metabolomically characterized by 1H-NMR fingerprinting analysis and principal 
component analysis (PCA). The content of alkaloids was additionally determined by RP-
HPLC-DAD. Functional characterization was achieved by the determination of cell 
proliferation and by transcriptomics-based techniques (Whole Genome Gene Expression 
Microarrays v2, Agilent Technologies) in HepG2 cells after exposure to the different extracts.  
Results: Based on data from 1H-NMR fingerprints and RP-HPLC analyses the different 
extracts showed a divergent composition of constituents depending on the solvent used. 
HepG2 liver cells responded differentially to the four extracts. Microarray analysis revealed a 
significant regulation of genes and signal cascades related to biotransformation. Also liver-
toxic signal cascades were activated. Neither the activated genes nor the proliferation 
response could be clearly related to the differing alkaloid content of the extracts.  
Conclusion: Different manufacturing processes lead to different herbal preparations. A 
systems biology approach combining a metabolomic plant analysis with a functional 
characterization by gene expression profiling in HepG2 cells is an appropriate strategy to 
characterize variations in plant extracts. Safety assessments of herbal substances may 
benefit from such complementary analyses.   
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Gene abbreviations: 
AhRR: aryl-hydrocarbon receptor repressor; AKR1B10: Aldo-keto reductase family 1 
member B10; AKR1C4: Aldo-keto reductase family 1 member C4; BAAT: Bile Acid-CoA: 
Amino Acid N-Acyltransferase; CHST10: Carbohydrate sulfotransferase 10; CHST14: 
Carbohydrate sulfotransferase 14; Cyp1A1: Cytochrome P450 family 1 member A1; 
CYP19A1: Cytochrome P450 family 19 member A1; Cyp1B1: Cytochrome P450 family 1 
member B1; CYP24A1: Cytochrome P450 family 24 member A1 (1,25-dihydroxyvitamin D3 
24-hydroxylase); CYP26A1: Cytochrome P450 family 26 member A1; CYP27C1: 
Cytochrome P450 family 27 member C1; CYP2A7: Cytochrome P450 family 2 member A7; 
CYP2B6: Cytochrome P450 family 2 member B6; CYP2A7: Cytochrome P450 family 2 
member A7; CYP2C18: Cytochrome P450 family 2 member C18; CYP3A4: Cytochrome 
P450 family 3 member A4; CYP3A7: Cytochrome P450 family 3 member A7; CYP4V2: 
Cytochrome P450 family 4 member V2; CYP8B1: Cytochrome P450 family 8 member B1; 
EGR2: Early growth response protein 2; GLYATL1: Glycine-N-Acyltransferase-Like 1; 
GSTO2: glutathione S-transferase omega 2; GSTP1: Glutathione S-transferase P; HMOX1: 
heme oxygenase (decycling) 1; HS3ST3A1: Heparan sulfate glucosamine 3-O-
sulfotransferase 3A1; HTR3A: 5-hydroxytryptamine receptor 3A; IGFBP1: Insulin-like growth 
factor-binding protein 1; KCNAB3: Voltage-gated potassium channel subunit beta-3; 
SULT1C3: Sulfotransferase 1C3; SULT1E1: Sulfotransferase 1C3; SULT4A1: 
Sulfotransferase 1C3; UGT2A3: Uridine 5'-diphospho-glucuronosyltransferase 2A3; 
UGT2B11: Uridine 5'-diphospho-glucuronosyltransferase 2B11  
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3.2 Introduction 
Medicinal plants and products derived thereof have a long tradition of therapeutic use and 
are widely accepted in the population. The quality of medicinal plants is a basic requirement 
for the safety of herbal preparations. In terms of quality requirements, the authentication of 
herbal substances is indispensable. In this context, molecular biological methods were tested 
successfully for their applicability in the identification of herbal substances (Kersten T., 2008). 
For safety assessment, several established in vitro and in vivo “toxicological” methods are 
available: for example the comet assay determines DNA strand breakage or the T-cell-
dependent antibody response assesses the antibody response to immunization. However, in 
the field of regulatory science there exists the necessity to investigate novel technologies, 
including functional genomics, proteomics, metabolomics, high-throughput screening and 
systems biology in order to replace current toxicology assays used for drug approval 
(Hamburg M., 2011). In future investigations it is important to characterize the toxicant/s with 
additional complementary methods. Thus, the chemical profile of a plant-derived extract, 
together with data on its cellular responses, toxicological findings and extrapolated effects of 
dose-response investigations have to be taken into account for the compilation of an overall 
picture (Hartung T., 2011; Krewski D., 2010; Wilkening S., 2003). 
In contrast to single substances, plant extracts present a challenge, as they are complex 
mixtures. Often, plant extracts are characterized by marker substances used for the 
standardization of herbal substances. But multicomponent mixtures can have synergistic 
effects, which may arise due to the combination of many components of an herbal 
preparation (Wagner H., 2006) not covered by the determination of marker substances 
alone. 
In this study Chelidonii herba was used as a model for our investigations. In literature, there 
are several reports on liver toxicity associated with application of herbal preparations derived 
from Chelidonium majus L. (Papaveraceae) (De Smet P.A., 2002; Stickel F., 2003; Strahl S., 
1998; Teschke R., 2012).  
The secondary metabolites most abundant in C. majus L. are alkaloids, more than 20 of 
which are chemically identified. The most important alkaloids (fig. 7) are the 
benzophenanthridine alkaloids (sanguinarine, chelerythrine, chelidonine) and 
protoberberines (berberine, coptisine). But also organic acids like chelidonic acid (Shen Z., 
2001), citric acid, malic acid, or succinic acid were isolated from C. majus L., as well as 
saponins, choline and histamine, ferulic acid, caffeic acid and p-coumaric acid (Hahn R., 
1993) are present.  
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Fig. 7: Chemical structure of typical alkaloids in C. majus L.. 
In the European Pharmacopoeia there is a minimum content of 0.6% alkaloids specified, 
expressed as chelidonine for Chelidonii herba. For the investigations performed in the 
current study, four extracts with solvents of different polarities were used. The complex 
mixture of chemical constituents was characterized by 1H-NMR fingerprint analysis, which is 
a comprehensive approach in the characterization of the plant metabolome (Daniel C., 
2008). The content of the alkaloids chelidonine, protopine, coptisine, berberine, sanguinarine 
and chelerythrine was quantified by RP-HPLC. The chemical profile was correlated to effects 
on liver cells. Therefore, the liver proliferation was investigated in response to the different 
extracts and effects were further characterized by a transcriptomic approach. Alterations in 
the gene expression were monitored by microarrays, permitting the assessment of complete 
gene expression profiles induced by different compounds or extracts. By systems biological 
data evaluation it was possible to place data into a biological context. 
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3.3 Materials and methods 
Extraction of Chelidonii herba: 
The herbal substance was complying with the monograph in Ph. Eur. 8.0, 07/2012:1861. It 
was purchased from a local pharmacy and powdered by a mill. Chelidonii herba was 
extracted with four different extraction solvents (ethanol, ethanol 50% (V/V), dichloromethane 
and water). Respectively, 1.0 g of plant material was extracted with 10 ml of the appropriate 
solvent, frequently stirring at room temperature for 10 min. After filtering, the extraction 
procedure was repeated. The solvents were eliminated under reduced pressure and the 
dried extract was resolved in 500 µl deuterated dimethyl sulphoxide. Four replicates were 
performed for each extract. The sample material Chelidonii herba in analogy to voucher 
specimens was deposited at the Institute of Pharmaceutical Biology, University of Bonn. 
Quantification of alkaloids in Chelidonii herba extracts with high performance liquid 
chromatography (HPLC): 
Liquid/liquid extraction cartridges (Chem Elut CE 1010) were used for sample preparation. 
For separation of alkaloids a Synergy 4u Polar-RP (80Å, 250 x 4.6 mm column, 
Phenomenex) was used with a cartridge (SequrityGuard Cartidges, Polar RP 4 x 3.0 mm ID, 
Phenomenex). Alkaloids were detected by DAD-UV at 285 nm. Two different mobile phases 
were used: solvent A, 90% H2O adjusted to a pH of 2.5 with phosphoric acid/10% methanol 
(V/V) and solvent B, 30% H2O adjusted to a pH of 2.5 with phosphoric acid/70% methanol 
(V/V). Alkaloids were eluted using a linear gradient from 30% B to 60% B for the first 6 min, 
followed by a linear gradient from 60% B to 100% B in 23 min. Subsequently the column was 
washed for 6 min with 100% B and re-equilibrated to the starting conditions first by a linear 
gradient from 100% B to 30% B in 3 min and then an isocratic gradient (30% B) for 10 min. 
The solvent flow rate was adjusted to 1.0 ml/min. Spectral data for all peaks were recorded in 
the range of 200-600 nm. The alkaloids were identified by the comparison of retention times 
and UV spectra to the respective reference substances. Protopine was shown to elute first 
(17.3 min), followed by chelidonine (19.6 min) and coptisine (23.2 min). The peak obtained at 
26.1 min was identified as berberine, subsequently sanguinarine (29.9 min) and chelerythrine 
(32.3 min) eluted.  
A validated method of the German Homeopathic Pharmacopeia was applied. Regarding 
validation based on ICH guideline, linearity, precision of the instrument, precision of the 
method and limit of detection was determined (International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005). The 
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determination of linearity indicated R2=0.99 for all used reference substances. Precision of 
the instrument showed a relative standard deviation of 3.43% and 5.65% for coptisine and 
protopine, respectively. Standard deviation was calculated based on six replicates of the 
Chelidonii herba extracts, each injected twice (10µl). 
1H-NMR spectroscopy and PCA: 
1H-NMR spectra of extracts were recorded with a Bruker advance 300 DPX instrument 
(temperature 25 °C, 64 scans). Calibration of spectra was performed according to signals of 
incomplete deuterated solvents. Data were processed using TOPSPIN software. Data 
evaluation by PCA was done with AMIX software (Bruker). Data from δ 0 to δ 10 ppm were 
included. The region from δ 2.2 to δ 5.5 ppm was excluded to eliminate the effects of signals 
from water and the solvent peak of DMSO (2.54 ppm) in the extract. The bucket width was 
0.05 ppm and data were integrated according to the sum of intensities. Four replicates of 
each extract were recorded by 1H-NMR.  
Preparation of total RNA: 
Total RNA was isolated from HepG2 cells using RNeasy Mini Kit (Qiagen, Germany) 
following the manufacturer’s instructions.  
Whole genome microarray: 
The quality of RNA was examined by the RIN-values (Agilent 2100 Bioanalyzer). The 
concentration and purity of extracted RNA was measured using an UV-visible spectrometer 
(NanoDrop 1000; Thermo Fisher Scientific, Waltham, MA) by absorption at wavelengths of 
260 and 280 nm. RNA samples with a 260/280 nm absorption ratio > 1.8 and RIN > 9.5 were 
used in subsequent microarray analysis. For microarray profiles, fluorescence labeled cRNA 
samples were prepared from 100 ng RNA using reverse transcriptase. The amplification 
reaction with simultaneous introduction of Cy3-dCTP to the amplified complementary RNA 
(cRNA) was performed using a Quick Amp Labeling Kit for One-Color (Agilent Technologies). 
The concentration of the purified samples and the Cy3 dye incorporation efficiency was 
evaluated using a NanoDrop 1000 spectrophotometer. After fragmentation (60 °C, 30 min), 
the single colour cRNA samples were hybridized to a DNA chip (Whole Genome Gene 
Expression Microarrays v2, Agilent Technologies, 8x60K, 27958 Gene RNAs, 7,419 
lincRNAs) at 65 °C for 17 hours in a hybridization oven (Agilent Technologies). Four 
independent experiments were performed under each experimental condition.  
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qRT-PCR: 
After reverse transcription by random priming the resulting cDNA was used for qRT-PCR. 
Following initial denaturation (95 °C, 10 min), amplification was performed over 45 cycles 
(Light Cycler 480, Roche) with denaturation at 95 °C for 10 s and annealing with primers at 
temperatures shown in (tab. 1). 
Tab. 1: Primer used for qRT-PCR for validation of microarray results. 
Primer/Gene 
name 
NCBI 
accession 
code 
Primer sequence (5´→3´) 
Annealing 
temperature 
[°C] 
HMOXI_1 NM_002133.2 CCCACGCCTACACCCGCTAC 65 
HMOXI_2 NM_002133.2 GGTGGCACTGGCAATGTTGG 65 
EGR2_1 NM_000399.3 CCTTTGACCAGATGAACGGAGT 64 
EGR2_2 NM_000399.3 GCTGGCACCAGGGTACTGA 64 
IGFBP1_1 NM_000596.2 CACAGCAGACAGTGTGAGACAT 52 
IGFBP1_2 NM_000596.2 ATTTCATCTGGTTTCAGTTTTGTAC 52 
AhRR_1 NM_020731 CAGTTACCTCCGGGTGAAGA 59 
AhRR_2 NM_020731 CCAGAGCAAAGCCATTAAGA 59 
Cyp1A1_1 NM_000499.3 AACCTTTGAGAAGGGCCACA 55 
Cyp1A1_2 NM_000499.3 GACCTGCCAATCACTGTGTC 55 
Cyp1B1_1 NM_000104 CACTGCCAACACCTCTGTCTT 53 
Cyp1B1_2 NM_000104 CAAGGAGCTCCATGGACTCT 53 
HTR3A_1 NM_213621.3 CCCAAGCCACCAAGACTGATA 57 
HTR3A_2 NM_213621.3 GCCACATGGACCAGAGCATAAC 57 
GAPDH_1 NM_002046.4 CCACCCATGGCAAATTCCATGGCA 57 
GAPDH_2 NM_002046.4 CTAGACGGCAGGTCAGGTCCACC 57 
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Elongation was performed at 72 °C for 20 s. The size of PCR fragments was analyzed by 
agarose gel electrophoresis. Evaluation of gene expression was done with Light Cycler 480 
Software 1.5 and Cp-values were normalized to GAPDH. 
Data processing and statistics: 
Hybridized and washed microarrays were scanned using an Agilent Scanner (Agilent 
Technologies) with Feature Extraction Software (Agilent Technologies). Fluorescence 
intensity data were imported to GeneSpring GX version 12.5 (Agilent Technologies) with the 
quantile scaling normalization. Before analysis, four data-filtration steps were conducted to 
exclude low-quality data to guarantee the accuracy of the statistical analysis. In the first step, 
spots with lower intensities than the threshold, which was determined based on the 
intensities of the Agilent RNA Spike-Mix, were filtered out to exclude spots weaker than 
background noise. In the second step, spots with saturated intensities and near-background 
intensities were filtered out using the ‘flag’ function of the Feature Extraction Software. In the 
third step, spots with large variance among the four repeated experiments (coefficient value 
> 50%) were filtered out. The final filtration step was conducted based on the fold increase. 
Statistical analysis of the genes remaining after the four filtration steps was performed with a 
t-test corrected using the Benjamini and Hochberg false discovery rate (Benjamini Y., 1995). 
Genes were considered as up- or down-regulated with a fold ≥ 2 and ≤ -2 and a p < 0.05.  
These processed data were used for further analysis by Ingenuity Systems Inc. Reedwood 
City, USA. Ingenuity data base was used as reference set. In the networks interaction 70 
molecules were set and all data sources were integrated in data analysis. Data were 
compared to the human reference data (Tissues and Primary Cells not otherwise specified, 
Cells not specified and other cells; Organ systems liver and other cells not otherwise 
specified).  
Treatment of HepG2 cells with plant extracts: 
HepG2 cells were purchased from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures GmbH and were used between passages 3 and 12. The 
cells were maintained in T75 flasks in RPMI 1640 medium supplemented with 10% fetal 
bovine serum, 1% penicillin/streptomycin solution (100 U/ml) and 1% L-glutamine. The cells 
were constantly incubated in humidified atmosphere at 5% CO2 and 37 °C. 
When the cells were about 80% confluent, they were treated with trypsin and harvested by 
centrifugation. Cells were counted and an equal number (1.0 x 106 cells/5 ml media) was 
transferred to each experimental plate (5 cm Ø) for treatment with the different extracts on 
the following day. Cells were treated with the extracts in a concentration of 1:501. The 
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vehicle treated cells (1% DMSO) served as a control group. Four replicates were performed 
for each experimental condition.  
Cell growth and proliferation assay using xCELLigence system: 
About 7500 HepG2 cells were seeded to each well. After 24 h, medium containing the 
extracts in a concentration of 1:501 adjusted to 1% DMSO or medium containing 1% DMSO 
as solvent control was added, respectively. The cell index was monitored every 15 min.  
3.4 Results 
NMR fingerprint analysis: 
The spectra of the ethanolic, ethanolic 50% (V/V), dichloromethane and aqueous Chelidonii 
herba extracts were recorded by 1H-NMR in order to characterize the groups of constituents 
of Chelidonii herba. This method is a comprehensive approach, where the complexity of 
extracts can be shown, in contrast to methods, where just marker substances are analyzed. 
The data of the 1H-NMR spectra were statistically evaluated by PCA (fig. 8).  
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Fig. 8: Score plot of PCA for PC1 and PC2 of the 
1
H-NMR spectra of the 
extracts of Chelidonii herba performed with different solvents. Each extract 
was recorded in four replicates. 
Discrimination between the four different extracts was achieved. Replicates of the different 
extracts are clustering with regards to their extraction solvent. The distribution of the clusters 
demonstrates that the ethanolic and dichloromethane extract as well as the aqueous and the 
ethanolic 50% (V/V) extract were similar to each other, respectively.  
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To identify classes of compounds responsible for the distribution, the loading plot (fig. 9) was 
evaluated.  
 
 
Fig. 9: Loadings for PC1 (blue) and PC2 (black). The scaling corresponds to the 
chemical shifts [ppm] of the 
1
H-NMR spectra. Data in the range of δ 2.2 to 
δ 5.5 ppm were excluded. 
The range between δ 2.2 and δ 5.5 ppm was excluded, because of water residues in the 
extracts. The main differences between the extracts are found in the region from 0-2.2 ppm, 
where most of the protons of terpenoids, steroids and organic acids resonate. In the region 
between δ 5.25 and δ 7.25 ppm, protons attached to phenylpropanoids, flavonoids, phenolics 
and tannins cause resonance signals. In this region differences between the extracts can be 
observed. 1H-NMR resonances of alkaloids like chelidonine, protopine, coptisine, 
sanguinarine, chelerythrine and berberine are expected in the range of δ 7.5 to δ 10 ppm. As 
the loading plot shows, discrimination of PCA does not result from the different alkaloid 
content of the extracts. 
Quantification of Chelidonii herba alkaloids by RP-HPLC: 
A more detailed characterization of the different Chelidonii herba extracts was done by 
quantifying chelidonine, protopine, sanguinarine, coptisine, chelerythrine and berberine of the 
Chelidonii herba extracts by RP-HPLC (tab. 2). The dichloromethane extract showed the 
highest total alkaloid content (8.11 mg/ml extract; 4.06 mg/g dry weight). The content of the 
alkaloid chelidonine (7.15 mg/ml extract) was higher compared to the other Chelidonii herba 
extracts. The total alkaloid content of the ethanolic extract (5.93 mg/ml extract; 2.96 mg/g dry 
weight) and the ethanolic 50% (V/V) extract (4.74 mg/ml extract; 2.37 mg/g dry weight) was 
higher compared to the aqueous extract (0.94 mg/ml extract; 0.47 mg/g dry weight).  
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Tab. 2: Alkaloid composition of different extracts of Chelidonii herba. Quantification of 
alkaloids was obtained by RP-HPLC-DAD (285 nm). 
 
 
Ethanolic 
extract 
50 % (V/V) 
ethanolic 
extract 
Dichloro- 
methane 
extract 
Aqueous 
extract 
  
± SD 
 
± SD 
 
± SD 
 
± SD 
Protopine 
(mg/ml) 
0.44 0.06 0.72 0.09 0.10 0.02 0.14 0.08 
Chelidonine 
(mg/ml) 
3.67 1.40 2.16 0.16 7.15 2.36 0.31 0.17 
Coptisine 
(mg/ml) 
1.32 0.40 1.43 0.24 0.40 0.07 0.17 0.11 
Berberine 
(mg/ml) 
0.14 0.01 0.15 0.00 0.13 0.00 0.13 0.01 
Sanguinarine 
(mg/ml) 
0.33 0.04 0.25 0.05 0.31 0.07 0.18 0.02 
Chelerythrine 
(mg/ml) 
0.03 0.00 0.02 0.01 0.02 0.01 0.00 0.01 
total alkaloids 
(mg/ml) 
5.93  4.74  8.11  0.94  
total alkaloids 
(mg/g dry 
weight) 
2.96  2.37  4.06  0.47  
HepG2 cell proliferation: 
Effects of different Chelidonii herba extracts on liver cells were investigated. The ethanolic 
and dichloromethane extract containing Chelidonii herba extract were applied with 11.84 
µg/ml and 16.19 µg/ml content of total alkaloids, respectively. HepG2 cells were exposed to 
the 50% (V/V) ethanolic and the aqueous extract in a concentration of 9.46 µg/ml and 1.88 
µg/ml, respectively. Each extract was applied to the cells in a dilution of 1:501 adjusting 1% 
of DMSO, respectively. The aqueous extract did not exhibit cytotoxic effects on HepG2 cells 
compared to the solvent control. After six hours of exposure to the aqueous extract 105% of 
the HepG2 cells were viable in relation to DMSO control (fig. 10).  
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Fig. 10: Effects of different Chelidonii herba extracts on HepG2 liver cells. Cell proliferation 
is set into relation to control and treatment start. Extracts were applied to the cells in a 
concentration of 1:501. Values are expressed as mean ±SEM of at least 3 to 12 replicates. 
The strongest effects on proliferation of the liver cells was observed for the ethanolic extracts 
(ethanol and ethanol 50% (V/V)) of Chelidonii herba. After six hours of exposure to the 
ethanolic extract 58% and 73% of the HepG2 cells were viable, respectively. Less cytotoxic 
effects were observed for the dichloromethane extract. 77% of the HepG2 cells were viable 
after six hours of exposure to the dichloromethane extract.  
Whole genome microarrays: 
In order to explore cellular effects of the different Chelidonii herba extracts at the genetic 
level, expression profiling was carried out in HepG2 cells. The initial data analysis revealed 
that each treatment with respect to the type of extract showed a distinct expression profile. In 
total, 2,861 genes were regulated due to the treatment with the dichloromethane Chelidonii 
herba extract, the regulation of 1,871 genes was different from that of the control for the 
aqueous Chelidonii herba extract, 1,850 genes were differently modulated when the cells 
were exposed to the ethanolic extract, and the expression of 695 genes was altered as a 
result of the treatment with the ethanolic 50% (V/V) extract. 
Data evaluation with IPA showed that signal cascades associated with toxicity and 
biotransformation were activated (fig. 11). Signal cascades involved in oxidative stress, fatty 
acid metabolism or liver damage were induced. An increase in the permeability transition or 
the transmembrane potential of mitochondria and mitochondrial membranes was activated 
significantly for at least one condition in HepG2 cells. Following exposure to the ethanolic 
extract seven signal cascades were activated. Respectively, six and two signal cascades 
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were activated for the ethanolic 50% (V/V) and the dichloromethane extract. No signal 
cascades were induced in HepG2 cells after exposure to the aqueous extract. 
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The signal pathway, which was significantly regulated by all four treatments, is “Cytochrome 
P450 Panel-Substrate is a Xenobiotic”. All other signal pathways related to biotransformation 
were activated at least by one extract or by two extracts. Genes involved in biotransformation 
that were regulated significantly in at least one condition are shown in (tab. 3).  
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Tab. 3: Fold changes of genes related to biotransformation after exposure to the different 
Chelidonii herba extracts on HepG2 cells. Fold changes of genes, which are related to 
biotransformation were obtained from microarray experiments by data evaluation (Genespring 
12.5). Values in bold indicate statistical significance by at least twofold and p ≤ 0.05. 
 
Gene 
Dichloromethane 
extract 
Ethanolic extract 
Ethanolic extract 
50% (V/V) 
Aqueous 
extract 
AKR1B10 1.5822 2.0252 1.9929 1.2447 
AKR1C4 -1.161 2.7486 2.1811 -1.2813 
BAAT -5.5898 -2.4609 -2.0001 -2.994 
CHST10 -2.7535 -1.5089 -1.2222 -1.8048 
CHST14 -2.2993 -1.4761 -1.072 -1.6347 
CYP19A1 1.1568 2.2508 2.4009 1.1475 
CYP1A1 1.5768 2.9473 3.2499 1.4064 
CYP1B1 2.9442 3.2531 4.1636 2.2513 
CYP24A1 2.31 3.9019 2.7159 -1.244 
CYP26A1 3.5888 3.5292 1.856 1.04 
CYP27C1 1.1677 -1.0281 2.8781 1.223 
CYP2A7 1.4945 1.4648 1.5285 2.5271 
CYP2B6 1.5528 2.2208 1.4477 1.6054 
CYP2C18 1.1694 1.5978 3.0097 1.4221 
CYP3A4 5.4536 6.4891 5.4454 3.2177 
CYP3A7 -2.6684 -1.1983 -1.1357 -2.8465 
CYP4V2 -2.8117 1.1533 1.1997 -1.654 
CYP8B1 -1.7735 -3.4139 -2.1441 1.1904 
GLYATL1 -3.0002 -4.1781 -2.4801 -2.4961 
GSTO2 -1.7483 -1.5308 -1.3509 -2.1757 
GSTP1 3.8747 2.8508 2.8556 2.5285 
HS3ST3A1 -1.0795 -1.0437 1.2999 2.3288 
KCNAB3 -2.3195 -1.7664 -1.5293 -1.7743 
SULT1C3 -1.7304 -2.0568 -1.9581 1.1393 
SULT1E1 -5.7103 -2.9995 -2.6536 -3.2872 
SULT4A1 2.00 1.9249 1.6726 1.5822 
UGT2A3 -2.2794 -1.4233 -1.1904 -1.9758 
UGT2B11 -2.6812 -2.4336 -1.8786 -2.1003 
30 
Exposure of cells to the dichloromethane and the ethanolic extracts led to significant 
regulation of 15 and 16 genes relevant to biotransformation, respectively. Regarding 
biotransformation, 12 differently regulated genes were identified for the ethanolic 50% (V/V) 
extract, and the regulation of 11 genes was altered following exposure to the aqueous 
extract. 
qRT-PCR: 
Data obtained by microarray were verified by qRT-PCR for selected genes (fig. 12). Results 
of qRT-PCR display minor differences in fold changes, but overall confirmed the results 
obtained by microarray analysis. 
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Fig. 12: Fold changes of the gene expression measured by microarray and qRT-PCR. Data 
obtained by qRT-PCR were normalized to GAPDH and set into relation to solvent control 
(AhRR: aryl-hydrocarbon receptor repressor, Cyp1A1: Cytochrome P450 family 1 member 
A1, Cyp1B1: Cytochrome P450 family 1 member B1, IGFBP: Insulin-like growth factor-
binding protein 1, EGR2: Early growth response protein 1, HTR3A: 5-hydroxytryptamine 
receptor 3A, HMOX: heme oxygenase (decycling) 1). 
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3.5 Discussion 
The quality and safety of herbal substances are important aspects in drug approval. Clinical 
double-blinded studies are rare in the field of herbal medicinal products, compared to studies 
on approved chemically-defined substances. Technical development and the avoidance of 
animal experiments are driving forces to investigate the applicability of new methods in the 
characterization of plant extracts; hence, to get a first insight for their potential prospects in 
regulatory affairs of herbal substances/herbal preparations.  
In the present study, the 1H-NMR fingerprint of Chelidonii herba extracted with solvents of 
different polarities was analyzed and the alkaloid content was determined. Cell proliferation 
of HepG2 liver cells was investigated, as it is considered that Chelidonii herba may have 
toxic effects on the liver, as several reports in literature described (Benninger J., 1999; De 
Smet P., 2002; Stickel F., 2003; Strahl S., 1998). 
Plant extracts are always multicomponent mixtures. 1H-NMR fingerprints of Chelidonii herba 
extracts showed that the latter differ in their composition regarding the groups of 
constituents. According to the 1H-NMR spectra and the loading plot), discrimination of the 
different extracts resulted from plant constituents associated with a big range of metabolites 
suggested to include terpenoids, steroids, organic acids, phenylpropanoids, flavonoids, 
phenolics and tannins. Resonance signals corresponding to the above-named plant 
constituents were obtained in the 1H-NMR spectra of the dichloromethane and the ethanolic 
Chelidonii herba extracts. 
For both ethanolic extracts the alkaloid content quantified by RP-HPLC differed only by about 
1 mg/ml extract (ethanolic extract 5.93 mg/ml extract; ethanolic 50% (V/V) 4.74 mg/ml 
extract). The dichloromethane extract showed the highest content of the total alkaloids (8.11 
mg/ml). Only a minor amount of alkaloids was extracted with water (0.94 mg/ml). As 
investigations of cell proliferation demonstrated, each extract of Chelidonii herba displayed 
different effects. Although the highest amount of total alkaloids was found in the 
dichloromethane extract, the strongest inhibition of proliferation of HepG2 cells was observed 
for the treatment with the ethanolic extract, suggesting that not exclusively alkaloids cause 
toxicity. This is also supported by the fact that relative proliferation rates of cells treated with 
the dichloromethane and the ethanolic 50% (V/V) extract were comparable (77 and 73% 
relative cell proliferation, respectively), though the total alkaloid content in the 
dichloromethane extract was nearly twice as high as in the ethanolic 50% (V/V) extract. 
Earlier studies, reported in literature, analyzed cytotoxic effects of the different alkaloids in 
HepG2 cells. IC50 values of chelidonine were 34.50 µM (12.19 µg/ml) after 24 h (El-Readi M., 
2013), the corresponding IC50 values of berberine and coptisine were 129.56 µM (48.17 
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µg/ml) and 202.33 µM (64.81 µg/ml), respectively (Yi J., 2013). Sanguinarine and 
chelerythrine showed IC50 values between 5 and 10 µM (24 h) (Zdarilova A., 2006), while 
protopine did not show a significant change in relation to the control at a concentration of 75 
µM after 24 h (Vrba J., 2011). In this study, the dichloromethane extract was very rich in 
chelidonine in relation to the other investigated Chelidonii herba extracts. Even with regard to 
the IC50 values of the quantified alkaloids, the phytochemical characteristics indicate that the 
alkaloid content is not exclusively responsible for the antiproliferative effect of the extracts.  
Microarray data evaluation of the present study showed that each extract caused a distinct 
expression pattern. For Equisetum arvense derived from different origins, discriminatory 
results in hierarchical cluster analysis of gene expression profiling in Saccharomyces 
cerevisiae were observed (Cook R., 2013). Discriminatory expression profiles in blood 
samples and subsequent different mode of actions were also observed in rats after their 
treatment with different fractions of a Salix spec. extract (Ulrich-Merzenich G., 2012). This 
indicates the specificity of transcriptome investigations.  
By further data evaluation obtained with the different Chelidonii herba extracts the biological 
processes correlated to liver toxicities were analyzed. Most significant activated signal 
cascades related to toxicity were found in biotransformation processes. HepG2 cells exposed 
to the dichloromethane (15 genes) or the ethanolic extract (16 genes) showed the highest 
number of regulated genes related to biotransformation processes. For the ethanolic 50% 
(V/V) extract 13 genes and for the aqueous extract 11 genes were induced, respectively. It is 
noticeable that the higher the quantity of alkaloids was, but also the more plant constituents 
were extracted as indicated by 1H-NMR fingerprint, the more genes were regulated in 
microarray experiments that play a role in biotransformation.  
As microarray results showed, mRNA levels of Cyp1A1 and Cyp1B1 were induced in HepG2 
cells. Protopine was shown to induce the formation of mRNA of Cyp1A1 in HepG2 cells 
without changing the Cyp1A1 protein or activity (Vrba J., 2011). But Cyp1A1 is inducible by 
various herbal substances, e.g. by the flavonoids quercetin and kaempferol (Ciolino H., 
1999), catechins like epigallocatechin-3-gallate (Palermo C., 2005) or alkaloids like berberine 
(Chatuphonprasert W., 2011; Lo S., 2013; Salminen K., 2011; Vrzal R., 2005; Zhou C., 
2011). Cyp3A4 has a share of 30% of the relative abundance of cytochromes in the liver and 
plays a dominant role in drug metabolism (Rendic S., 1997). Exposure of HepG2 cells to all 
four Chelidonii herba extracts induced Cyp3A4 gene expression, which was shown earlier to 
be potentially mediated by alkaloids (Salminen K., 2011; Zhou C., 2011).  
Further data evaluation with IPA linked to liver-toxic effects confirmed the liver proliferation 
results. Most significantly regulated signal cascades and most antiproliferative effects, as cell 
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proliferation showed, were observed for the ethanolic extract. According to the microarray 
results, oxidative stress plays a role in hepatotoxicity. Oxidative stress can damage proteins, 
DNA and lipids in cells. Nrf2 is a transcription factor which is able to transactivate detoxifying 
enzymes and antioxidant enzymes (Itoh K., 1997).  
The most significantly activated cascade (“Increase in the Permeability Transition of 
Mitochondria and Mitochondrial Membranes”) indicates that mitochondria were depolarized. 
This is a key event in necrotic and apoptotic cell death (Lemasters J., 1998). The signal 
cascade “Increase in the Transmembrane Potential of Mitochondria and Mitochondrial 
Membranes” was observed for exposure to the ethanolic extract. The transmembrane 
potential of mitochondria is essential for the ATP production of the cell. Mitochondrial 
dysfunction may lead to alterations in the transmembrane potential; subsequently this may 
lead to apoptosis.  
Both ethanolic extracts of Chelidonii herba altered the fatty acid metabolism in HepG2 cells. 
The liver is involved in important aspects of lipid metabolism (fatty acid β-oxidation, 
lipogenesis and lipoprotein uptake and secretion). Hepatic stellate cell (HSC) activation was 
significantly activated by the ethanolic extract. HSCs may be activated by hepatotoxins, 
initiating a cascade of pro-inflammatory events. Continued liver injury may lead to tissue 
fibrosis and liver cirrhosis. Significant results for “Hepatic Fibrosis” were observed for the 
dichloromethane extract. “Liver Proliferation” and “Increased Liver Damage” were activated 
after exposure to the ethanolic 50% (V/V) extract of Chelidonii herba.  
The data evaluated with IPA indicate that extracts of Chelidonii herba induce also 
nephrotoxic cascades. The signal cascade “Renal Glomerulus Panel” was activated for the 
ethanolic and dichloromethane extract of Chelidonii herba. The signaling cascade “Renal 
necrosis/Cell Death” was significantly regulated for the ethanolic and ethanolic 50% (V/V) 
extract of Chelidonii herba in HepG2 cells.  
Overall, several signal cascades attributable to hepatotoxicity are regulated. But the 
relevance of in vitro results obtained with cell culture models for human is difficult to estimate 
and still under debate. In previous studies, biotransformation properties of HepG2 cells and 
primary liver cells were compared and showed similar results (Wilkening S., 2003). The 
relevance of data obtained by microarray experiments should be further proven on the 
protein or cellular level.  
Herbal preparations are defined according to the manufacturing process. Extracts obtained 
with the different solvents showed a different phytochemical composition and subsequently 
different biological activities. This emphasizes the importance of standardized manufacturing 
processes in herbal drug preparation.  
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In conclusion, the results demonstrate that a combination of the metabolomic 
characterization and the analysis of the transcriptome by microarrays is an appropriate 
strategy to characterize plant extracts. The approach provides complementary information, 
which often may be more representative for the characterization of a complex mixture than 
analysis of single compound or groups of constituents. The analysis of the microarray 
experiments with bioinformatics tools can be differentially attributed to specific extracts. For 
safety assessment of extracts of Chelidonii herba, it is particularly interesting that signal 
cascades correlated with biotransformation or toxicity has been identified. However, the 
current set of available data is limited and not permitting to draw any regulatory conclusion. 
Further studies are necessary to evaluate the suitability of different cell culture models and 
their relation to results obtained by liver proliferation studies. 
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4 A combined approach to characterize Cimicifugae racemosae 
rhizoma by metabolomic fingerprinting and gene expression 
profiling  
4.1 Abstract 
Background: Herbal substances and preparations thereof are used traditionally around the 
globe. In the last years, technical progress on metabolomics and transcriptomics has been 
achieved. Cimicifugae racemosae rhizoma is an herbal substance for which several reports 
associated to liver-toxic effects exist. In the present study, metabolomic and transcriptomic 
methods were used to characterize the chemical profile and functional effects of Cimicifugae 
racemosae rhizoma complementary to standard methods. The triterpene glycosides of 
Cimicifugae racemosae rhizoma extracts were quantified. Extracts of different composition 
were prepared, as three solvents of different polarity were used (ethanol, dichloromethane 
and ethanol 50% (V/V) (four replicates each). In addition to the standard method described in 
the European Pharmacopeia, the extracts were characterized by 1H-NMR analysis and PCA. 
HepG2 cell proliferation was investigated after exposure to different extracts. Gene 
expression profiles of HepG2 cells were investigated by microarrays.  
Results: By HPLC-ELSD it was demonstrated that the content of triterpene glycosides varied 
in the different extracts (total triterpene glycoside content: ethanolic extract 6.1 mg/ml; 
dichloromethane extract 4.4 mg/ml, ethanolic 50% (V/V) extract 2.9 mg/ml). 1H-NMR 
spectrometric analysis of the different extracts showed that they contained varying herbal 
constituents. The different extracts were applied to HepG2 cells in a concentration of 1:501 
(total triterpene content applied to HepG2 cells: ethanolic extract: 12.2 µg/ml, 
dichloromethane extract: 8.8 µg/ml, ethanolic 50% (V/V) extract: 5.8 µg/ml) and provoked 
different effects on HepG2 cell proliferation. Gene expression data showed that all different 
extracts influenced signal cascades related to cholesterol biosynthesis and induced statin-
related responses. Additionally, signal cascades assignable to liver toxicity (e.g. liver 
necrosis, cell death) and the induction of several cytochromes were identified, mainly for the 
ethanolic and the dichloromethane extract. 
Conclusion: 1H-NMR analysis and gene expression profiling techniques are useful for the 
comprehensive characterization of herbal preparations. The results of the present study 
support the necessity of appropriate quality assurance and characterization of herbal 
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substances and preparations thereof. For the assessment of quality and safety of herbal 
medicinal products a comprehensive approach by using 1H-NMR spectroscopy analysis and 
the investigation of the transcriptome approach proved to be valuable and complementary to 
already established methods.  
Gene abbreviations:  
CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2; CYP2C9: cytochrome 
P450, family 2, subfamily C, polypeptide 9; CYP2D6: cytochrome P450, Family 2, subfamily 
D, polypeptide 6; CYP51A1: cytochrome P450, family 51, subfamily A, polypeptide 1; 
DHCR7: 7-dehydrocholesterol reductase; EDN1: endothelin 1; FDFT1: farnesyl-diphosphate 
farnesyltransferase 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HMGCR: 3-
hydroxy-3-methylglutaryl-CoA reductase; HMGCS: 13-hydroxy-3-methylglutaryl-CoA 
synthase 1; HMOX1: heme oxygenase (decycling) 1, IDI1: isopentenyl-diphosphate delta 
isomerase 1; IGFBP1: insulin-like growth factor-binding protein 1; LDLR: low density 
lipoprotein receptor; LSS: lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase); 
MSMO1: methylsterol monooxygenase 1; MVD: mevalonate (diphospho) decarboxylase; 
MVK: mevalonate kinase; SQLE: squalene epoxidase; SREBP: sterol regulatory element 
binding transcription factor 
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4.2 Background 
In modern medicine substantial progress could be observed in recent decades, i.e. the use of 
recombinant proteins. Nevertheless, traditional herbal substances considerably contribute to 
the human health care. However, it is mandatory to apply safe herbal medicines with 
adequate quality. Herbal substances and preparations thereof are multicomponent mixtures; 
hence, they are very different from chemically-defined medicinal products. The active 
principle from herbal substances is often unknown and the complex mixtures are regarded as 
active substance. The multicomponent nature of herbal medicines complicates their 
analytical evaluation. 
For regulatory affairs of herbal medicines research on characterization of herbal preparations 
is of major interest, since the currently applied standard methods have shown limitations. It 
has already been described that the phytochemical characterization using marker 
substances is not always sufficient for an adequate characterization of herbal substances 
and preparations thereof. Hence, methods related to metabolomics, i. e. the complete 
phytochemistry, and transcriptomics, i. e, the overall biological response need to be further 
examined for their usefulness in evaluating the quality and safety of an herbal medicine.  
NMR spectroscopy is a frequently used metabolomic technique (Kim H., 2010; Schripsema 
J., 2010; Wang X., 2011). The basis of this approach is a broad-spectrum analysis that takes 
into account the entire NMR-sensitive metabolite content, extracted from the sample in 
question. In the present research, a multivariate statistical analysis method, i. e. principal 
component analysis (PCA), was applied to analyze 1H-NMR spectra of herbal extracts 
(Daniel C., 2008). PCA is an unsupervised and therefore unbiased technique for multivariate 
analysis.  
The functional effects of the herbal preparations were characterized by determination of the 
cell proliferation rate of HepG2 liver cells after exposure to differently prepared extracts 
containing Cimicifugae racemosae rhizoma. Additionally, transcriptomics methods, such as 
microarrays were used to identify differently regulated genes and place them into a biological 
context by systems biological data evaluation.  
Cimicifugae racemosae rhizoma (Actaea racemosa L., syn. Cimicifuga racemosa L.; 
Ranunculaceae) is a widely used herbal substance and has been linked to a variety of 
benefits for specific health problems in women. According to the HMPC monograph on 
Cimicifugae racemosae rhizoma, the drug is indicated for the relief of menopausal 
complaints such as hot flushes and profuse sweating (Committee on Herbal Medicinal 
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Products, 2010a). Questions have been raised about the safety of Cimicifugae racemosae 
rhizoma. Cases of liver toxicity were described for patients who were taking products derived 
from this herbal substance; subsequent evaluation found some products to be adulterated 
with other related herbal species (Patel N. and Derkits R., 2007; Gardiner P., 2008; Joy D., 
2008; Pierrard S. 2009; Vannacci A., 2009; Painter D., 2010). Since 2009, a graduated 
scheme has been effective concerning the risks of hepatotoxicity and the consumption of 
herbal preparations containing Cimicifugae racemosae rhizoma in Germany. This graduated 
scheme implies precautions and warnings with regard to the application of Cimicifuga 
containing preparations. Since the association of hepatotoxicity with application of 
Cimicifugae racemosae rhizoma is possible, this is an interesting model object to correlate 
the chemical profile and effects on liver cells with differently prepared extracts.  
Chemical constituents of a Cimicifugae racemosae rhizoma extract may comprise at least 
three major natural product groups: Cycloartenal-type triterpenes, phenolics and flavonoids 
(Chen S., 2002c; Li J., 2006). According to the HMPC monograph on Cimicifugae racemosae 
rhizoma, there is an ongoing discussion on the constituent(s) responsible for the 
effectiveness of Cimicifugae racemosa rhizoma. Therefore, the whole extract is considered 
as the active pharmaceutical ingredient. 
According to the HMPC monograph on Cimicifugae racemosae rhizoma, their preparations 
contain a complex mixture of 40-70 mg/g herbal substance of triterpene glycosides. The 
major constituents are actein, 23-epi-26-deoxyactein (syn. 27-deoxyactein), cimiracemoside 
A, acetylshengmanol-3-O-xyloside, cimigenol 3-O-arabinoside and cimigenol 3-O-xyloside 
(fig. 13) (Bedir E., 2000; Chen S., 2002c; He K., 2006; Shao Y., 2000; Watanabe K., 2002).  
 
 
Fig. 13: Chemical structure of actein. 
Caffeic, ferulic, isoferulic, fukinolic, fukiic and cimicifugic acid (Kruse S., 1999), as well as 
cimiracemates belong to the group of phenolics and were found in minor amounts (Chen S., 
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2002a; Chen S., 2002b). Guanidine alkaloids like cimipronidine were detected in Cimicifugae 
racemosae rhizoma only in smaller quantities (Fabricant D., 2005). 
The occurrence of the flavonoids formononetin and kaempferol has not been verified (Jiang 
B., 2006; Jiang B., 2011; Kennelly E., 2002; Struck D., 1997), except for two references (Al-
Amier H., 2012; Panossian A., 2004), which reported formononetin to occur in a ppm range. 
In current reports on Cimicifugae racemosa rhizoma, kaempferol was not detected (Struck 
D., 1997). For these natural products the involvement in estrogenic effects was discussed 
(Jarry H., 1985).  
4.3 Materials and Methods 
Plant material and preparation of extracts: 
Samples of Cimicifugae racemosae rhizoma were provided by Phytolab GmbH & Co. KG. In 
analogy to voucher specimen, herbal substance has been deposited at the University of 
Bonn, Institute of Pharmaceutical Biology.  
Cimicifugae racemosae rhizoma was extracted with three different extraction solvents 
(ethanol, ethanol 50% (V/V), dichloromethane). Four replicates were performed for each 
extract. Respectively 2.0 g of plant material was extracted with 20 ml of the solvent, 
frequently stirring at room temperature for 20 min. After filtering, the extraction procedure 
was repeated using 20 ml of the respective solvent. The extract was divided into two parts 
and the solvents were eliminated under reduced pressure. One half of the dried extract was 
solved in 500 µl deuterated dimethyl sulphoxide for 1H-NMR measurement. The remaining 
half of the dried extract was solubilized in 2.0 mL 50% (V/V) methanol and used for HPLC 
analysis.  
1H-Nuclear magnetic resonance (NMR) spectroscopy: 
1H-NMR spectra of extracts were recorded with a Bruker advance 300 DPX instrument 
(temperature 25 °C, 64 scans). Four replicates of each extract were recorded by 1H-NMR. 
Calibration of spectra was performed according to signals of incompletely deuterated 
solvents. Data were processed using TOPSPIN software.  
Principal component analysis: 
PCA was performed using TopSpinTM software (Bruker). Data from δ 0 to δ 10 ppm were 
included. The region from δ 2.3 to δ 5.0 ppm was excluded to eliminate the effects of water 
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signals and the solvent peak of DMSO (2.54 ppm) in the extract. The bucket width was 
0.05 ppm and data were integrated according to the sum of intensities.  
Quantification of triterpene glycosides in Cimicifugae racemosae rhizoma extracts: 
The triterpene glycosides were quantified using HPLC and evaporative light scattering 
detector (ELSD). HPLC analysis was carried out on an Agilent 1100 series instrument 
equipped with a quaternary pump, a four-channel-online degasser and an autosampler. 
ELSD chromatograms were recorded on a Sedere Sedex-75 (Alfortville, France) and 
chromatographic data were collected by Chemstation software (Agilent). The ELSD detector 
was set to 40 °C and the measurements were carried out in gain 9. The carrier gas was 
compressed air.  
With respect to the quantification of triterpene glycosides a validated method described in the 
European Pharmacopeia was used. Regarding validation based on ICH guideline, linearity, 
precision of the instrument and precision of the method was determined (International 
Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, 2005). The determination of linearity was performed using 
glycyrrhizic acid (R2=0.99), as described in the monograph, and additionally by using 27-
deoxyactein (R2=0.99). Linearity was analyzed using concentrations in the range of 76.5 to 
765.2 µg/ml and 50.7 to 505.6 µg/ml for glycyrrhizic acid and 27-deoxyactein, respectively. 
Precision of the instrument showed a relative standard deviation of 1.85% for 27-deoxyactein 
after six injections of this compound. Precision of the method showed a relative standard 
deviation of 5.9% after injection of six replicates of the dichloromethane Cimicifugae 
racemosae rhizoma extract. The injection volume was 10 µl and the investigated extracts 
were injected twice.  
The different Cimicifugae racemosae rhizoma extracts were filtered via 45 µm membranes. 
Chromatography was performed on a Zorbax Eclipse XDB C18 column (250 x 4.6 mm i.d., 5 
µm) with a flow rate of 1 mL/min. The column was equipped with an analytical guard column.  
The mobile phase consisted of 0.1% (V/V) formic acid (A) and 0.1% formic acid/acetonitrile 
50% (V/V) (B) The program of chromatography showed minor changes according to the 
pharmacopeial monograph: 0 min 50% B, 50 min 80% B. Finally, the column was washed for 
3 min with 95% B and re-equilibrated to 50% B for 5 min.  
Treatment of HepG2 cells with plant extracts: 
HepG2 cells were purchased from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures GmbH and were used between passage 3 and 12. The 
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cells were maintained in T75 flasks in RPMI 1640 medium supplemented with 10% fetal 
bovine serum, 1% penicillin/streptomycin solution (100 U/ml) and 1% L-glutamine. The cells 
were constantly incubated in humidified atmosphere at 5% CO2 and 37 °C. 
When the cells were to about 80% confluent, they were treated with trypsin and harvested by 
centrifugation. Cells were counted and an equal number (1.0 x 106 cells/5 ml media) were 
transferred to each experimental plate (5 cm Ø) for treatment with the different extracts on 
the following day. Cells were treated with the extracts in a concentration of 1:501. The 
vehicle treated cells (1% DMSO) served as a control group. Four replicates were performed 
for each experimental condition.  
Cell growth and proliferation assay using xCELLigence system: 
About 7,500 HepG2 cells were seeded to each well. After 24 h, medium containing the 
extracts in a concentration of 1:501 adjusted to 1% DMSO or medium containing 1% DMSO 
as solvent control was added, respectively. The cell index was monitored every 15 min.  
Whole genome microarray: 
The quality of RNA was examined by the RIN-values (Agilent 2100 bioanalyzer). The 
concentration and purity of extracted RNA was measured using an UV-visible spectrometer 
(NanoDrop 1000; Thermo Fisher Scientific, Waltham, MA) by absorption at wavelengths of 
260 and 280 nm. RNA samples with a 260/280 nm absorption ratio > 1.8 and RIN > 9.5 were 
used in subsequent microarray analysis. For microarray profiles, fluorescently labeled cRNA 
samples were prepared from 100 ng RNA using reverse transcriptase. The amplification 
reaction with simultaneous introduction of Cy3-dCTP to the amplified complementary RNA 
(cRNA) was performed using a Quick Amp Labeling Kit for One-Color (Agilent Technologies). 
The concentration of the purified samples and the Cy3 dye incorporation efficiency was 
evaluated using a NanoDrop 1000 spectrophotometer. After fragmentation (65 °C, 30 min), 
the single colour cRNA samples were hybridized to a DNA chip (Whole Genome Gene 
Expression Microarrays v2, Agilent Technologies, 8x60K, 27,958 Gene RNAs, 7,419 
lincRNAs) at 65 °C for 17 hours in a hybridization oven (Agilent Technologies). Four 
independent experiments were performed under each experimental condition.  
qRT-PCR: 
After reverse transcription by random priming the resulting cDNA was used for qRT-PCR. 
Following initial denaturation (95 °C, 10 min), amplification was performed over 45 cycles 
(Light Cycler 480, Roche) with denaturation at 95 °C for 10 s and annealing with primers at 
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temperatures shown in tab. 4. Elongation was performed at 72 °C for 20 s. The size of PCR 
fragments was analyzed by agarose gel electrophoresis. Gene expression was evaluated 
with Light Cycler 480 Software 1.5 and CP-values were normalized to GAPDH. 
Tab. 4: Primer used for qRT-PCR for validation of microarray results. 
Primer/Gene 
Assignment 
NCBI 
accession 
code 
Primer sequence 
(5´→3´) 
Annealing 
temperature 
(°C) 
HMGCR_1 NM_000859 TGATTGACCTTTCCAGAGCAAG 52 
HMGCR_2 NM_000859 CTAAAATTGCCATTCCACGAGC 52 
EDN1_1 NM_001955.4 CCTGGACATCATTTTGGGTCAA 62 
EDN1_2 NM_001955.4 TCATGGTCTCCGACCTGGT 62 
HMOXI_1 NM_002133.2 CCCACGCCTACACCCGCTAC 65 
HMOXI_2 NM_002133.2 GGTGGCACTGGCAATGTTGG 65 
IGFBP1_1 NM_000596.2 CACAGCAGACAGTGTGAGACAT 52 
IGFBP1_2 NM_000596.2 ATTTCATCTGGTTTCAGTTTTGTAC 52 
GAPDH_1 NM_002046.4 CCACCCATGGCAAATTCCATGGCA 57 
GAPDH_2 NM_002046.4 CTAGACGGCAGGTCAGGTCCACC 57 
 
Data processing and statistics: 
Hybridized DNA chip slides were scanned using an Agilent Scanner (Agilent Technologies) 
with Feature Extraction Software (Agilent Technologies). Fluorescence intensity data were 
imported to GeneSpring GX version 12.5 (Agilent Technologies) with the quantile scaling 
normalization. Subsequently data were filtered to exclude low-quality data to guarantee the 
accuracy of the statistical analysis. In the first step, spots with lower intensities than the 
threshold, which was determined based on the intensities of the Agilent RNA Spike-Mix, 
were filtered to exclude weaker spots than background noise. Entities with saturated 
intensities and near-background intensities were filtered using the ‘flag’ function of the 
Feature Extraction Software. The final filtration was conducted based on the fold increase. 
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Statistical analysis of the remaining entities was performed with a t-test corrected using the 
Benjamini and Hochberg false discovery rate (Benjamini Y., 1995). Genes were considered 
as up- or down-regulated with a fold ≥ 2 and ≤ -2 and p ≤ 0.05.  
These processed data were used for further analysis by Ingenuity systems Inc. Reedwood 
city, USA. Filters were set for SurePrint G3 Human CGH Microarray 8*60K as reference set. 
In the networks interaction 70 molecules were set and all data sources were integrated in 
data analysis. Data were compared to all species (human, rat and mouse) and all available 
tissues and types of cells. 
4.4 Results 
1H-NMR spectroscopy and PCA: 
In total 1H-NMR spectra from twelve samples of Cimicifugae racemosae rhizoma, which were 
extracted with three different solvents, were analyzed. Differences in the spectra of the 
ethanolic, ethanolic 50% (V/V) and dichloromethane Cimicifugae racemosae rhizoma 
extracts were visually noticeable with regard to the extraction solvents, respectively. 
According to the spectra obtained for the ethanolic and dichloromethane extracts resonance 
signals assignable to terpenoids, phenylpropanoids and flavonoids were obtained.  
The differences of the 1H-NMR spectra were further ascertained by a pattern recognition 
approach. The different Cimicifugae racemosae rhizoma extracts were discriminated by PCA 
(fig. 14). 
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Fig. 14: Score plot of PCA for PC1 and PC2 of the 
1
H-NMR spectra of the extracts of 
Cimicifugae racemosae rhizoma. The extracts were prepared with different solvents; four 
replicates each. The extracts were recorded in DMSO-d6. 
With regard to the extraction solvent, replicates of the different extracts showed cluster 
formation. The first principal component (PC1) indicated 58.0% of the explained variance and 
the second principal component displayed 17.2%. No natural compound was precisely 
identified responsible for the differentiation of the extracts by the visual investigation of the 
spectra or by the loading plot (fig. 15).  
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Fig. 15: Loadings for PC1 (blue) and PC2 (black). The scaling corresponds to 
the chemical shifts [ppm] of the 1H-NMR spectra. Signals in the range of δ 2.2 
to δ 5.5 ppm were excluded. 
To identify classes of compounds responsible for the distribution, the loading plot was 
evaluated. Signals in the range between δ 2.3 and δ 5.0 ppm were excluded, because of 
overlapping signals from water residues in the extracts. According to the loading plot, the 
main differences between the extracts were found for resonance signals (δ 0- δ 2.3 ppm), 
which could be associated with protons from terpenoids, steroids, and organic acids. In the 
region between δ 5.0 and δ 6.7 ppm, protons attached to phenylpropanoids, flavonoids, and 
phenolics cause resonance signals and in this region differences between the extracts were 
observed. In the range of δ 7.5 to δ 10 ppm protons associated with alkaloids resonate. The 
loading plot indicated that for the classification of the extracts compounds like alkaloids 
contributed only to a limited amount.  
Quantification of triterpene glycosides in Cimicifugae racemosae rhizoma extracts: 
The triterpene glycosides in Cimicifugae racemosae rhizoma were quantified according to 
the method described in the monograph 7.5/2069 in the European Pharmacopeia (with minor 
modifications). As demonstrated in tab. 5 the ethanolic extract showed the highest content of 
triterpene glycosides (6.1 mg/ml and 12.2 mg/g of dry weight of Cimicifugae racemosae 
rhizoma). 24.6% of the content of triterpene glycosides corresponded to 27-deoxyactein. The 
dichloromethane extract contained 4.4 mg/ml triterpene glycosides, whereof 24.7% was 27-
deoxyactein. The triterpene glycoside content in the ethanolic extract 50% (V/V) obviously 
was lower (2.9 mg/ml) and 26.5% was 27-deoxyactein.  
  
loadings PC 1
loadings PC 2
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Tab. 5: Quantification of triterpenes glycosides of different Cimicifugae racemosae rhizoma 
extracts. Triterpenes glycosides were separated and detected by HPLC-ELSD. 
 
Total 
triterpene 
glycosides 
(mg/ml extract) 
Total 
triterpene 
glycosides 
(mg/g dry 
weight) 
27-
Deoxyactein 
(mg/ml extract) 
Total 27-
Deoxyactein 
(mg/g dry 
weight) 
Dichloromethane 
extract 
4.4 8.8 1.1 2.2 
Ethanolic extract 6.1 12.3 1.5 3.0 
50% (V/V) 
ethanolic extract 
2.9 5.8 0.8 1.5 
Cell proliferation of HepG2 cells after exposition to different Cimicifugae racemosae rhizoma 
extracts: 
The different Cimicifugae racemosae rhizoma extracts were investigated for effects on 
HepG2 liver cell proliferation (fig. 16). After six hours of exposure to the 50% (V/V) ethanolic 
extract 81% of cells were proliferating in relation to DMSO control. A stronger effect on 
hepatocellular cell proliferation was observed for the dichloromethane extract. Here, after six 
hours of exposure, 72% of cells were proliferating in relation to the control. The ethanolic 
extract showed an even more marked effect on cell proliferation (61% after six hours of 
exposure) than the dichloromethane Cimicifugae racemosae rhizoma extract.  
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Fig. 16: Effects of HepG2 liver cells after exposure to different Cimicifugae 
racemosae rhizoma extracts. Cell proliferation was set into relation to control 
and treatment start. Extracts were applied to the cells in a concentration of 
1:501. Values are expressed as mean ±SEM of at least 3 to 12 replicates. 
Microarray data analysis: 
Gene expression of HepG2 cells, exposed to the different Cimicifugae racemosae rhizoma 
extracts, was investigated at a time point of six hours of exposure. Preliminary investigations 
indicated that it is an eligible time point to cover the primary gene response.  
Microarray analysis revealed that exposure of the ethanolic extract induced most effects on 
gene expression, 522 genes were differently regulated. The dichloromethane extract 
significantly altered the regulation of 348 genes, while the ethanolic 50% (V/V) changed the 
expression of 51 genes in relation to control. 
Using IPA significantly regulated genes were investigated for affected signal cascades (fig. 
17). 
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Fig. 17: Signal cascades involved in canonical pathways (upper part), related to diseases 
and biofunctions (middle part), biotransformation and liver toxicity (lower part) of HepG2 
cells after exposure to different Cimicifugae racemosae rhizoma extracts. All extracts were 
applied in a dilution of 1:501; data were obtained by IPA data evaluation. Dark blue color: 
treatment with ethanolic extract, light blue color: treatment with ethanolic 50% (V/V) extract, 
turquoise colour: treatment with dichloromethane extract. Effects were considered as 
statistically significant, if values were exceeding a threshold of p > -log 1.31. 
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The ethanolic and dichloromethane extract significantly altered signal cascades and 
networks involved in the sterol biosynthesis, terpenoid biosynthesis and fatty acid and lipid 
biosynthesis.  
For HepG2 cells exposed to Cimicifugae racemosae rhizoma extracts the following signal 
cascades related to diseases and biofunctions emerged: “Lipid Metabolism”, “Small molecule 
Biochemistry” and “Vitamin and Mineral Metabolism”. Associated with these processes are 
the synthesis of cholesterol, sterols, lipids, terpenoids and steroids, the metabolism of 
cholesterol, membrane lipid derivatives and steroids, steroidogenesis and the concentration 
of lipids and long chain fatty acids. Related to metabolic diseases, dislipidemia, 
hypertriglyceridemia and hypercholesterolemia can be allocated to this context. Furthermore, 
the signal cascade “Organismal Injury and Abnormalities” showed significant results for all 
three different extracts.  
As there is a special interest for signal cascades related to toxicity of Cimicifugae racemosae 
rhizoma, the data were further analyzed with this regard (fig. 17). The relevance on 
cholesterol biosynthesis is reflected. Furthermore, involvement of cytochromes related to 
processes in metabolism or biotransformation is demonstrated, at least for the ethanolic 
extract. The impairment of mitochondria in toxicity-related signal cascades was shown for 
exposure of the ethanolic and the dichloromethane extracts, while no statistical significant 
effects were observed for the ethanolic 50% (V/V) extract. “Liver Necrosis/Cell Death”, 
“Renal Necrosis/Cell Death” and “Cardiac Hypertrophy” and the signal cascade “Increase in 
Liver Hyperplasia/Hyperproliferation” were altered significantly for the ethanolic and 
dichloromethane extracts but not for the ethanolic 50% (V/V) extract.  
Cellular responses and affected signal cascades to cholesterol biosynthesis were 
characterized more in detail (tab. 6). Several significantly regulated genes demonstrated to 
have an impact in cholesterol biosynthesis, in the sterol regulatory element-binding protein 
(SREBP), but also in the statin-related mediated cellular answer.  
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Tab. 6: Fold changes of genes related to cholesterol biosynthesis in HepG2 cells after 
exposure to the different Cimicifugae racemosae rhizoma extracts. Fold changes of genes, 
which are related to cholesterol biosynthesis, SREBP and statin-related cellular responses 
were obtained from microarray data evaluation (Genespring 12.5). Values in bold indicate 
statistical significance by at least twofold change in gene regulation and p ≤ 0.05. 
Gene Name 
NCBI 
accession 
code 
Dichloromethane 
extract 
Ethanolic 
extract 
Ethanol 50% 
(V/V) extract 
Cholesterol 
biosynthesis 
    
IDI1 NM_004508 2.62 2.81 1.94 
HMGCS1 NM_002130 2.84 2.91 2.16 
HMGCR NM_000859 2.59 2.62 2.11 
MVK NM_000431 2.15 2.27 1.67 
MVD NM_002461 3.36 3.28 2.73 
FDFT1 NM_004462 2.21 2.29 1.83 
DHCR7 NM_001360 2.19 2.43 1.79 
LSS NM_001001438 2.12 2.50 1.62 
SQLE NM_003129 2.56 2.58 2.29 
CYP51A1 NM_000786 2.16 2.30 1.72 
MSMO1 NM_006745 2.71 3.09 1.98 
Statin-related     
HMGCR NM_000859 2.59 2.62 2.11 
LDLR NM_000527 4.06 4.92 2.18 
FDFT1 NM_004462 2.21 2.29 1.83 
SQLE NM_003129 2.56 2.58 2.29 
SREBP     
HMGCR NM_000859 2.59 2.62 2.11 
LSS NM_001001438 2.12 2.50 1.62 
HMGCS1 NM_002130 2.84 2.91 2.16 
MVD NM_002461 3.36 3.28 2.73 
IDI1 NM_004508 2.62 2.81 1.94 
FDFT1 NM_004462 2.21 2.29 1.83 
SQLE NM_003129 2.56 2.58 2.29 
CYP51A1 NM_000786 2.16 2.30 1.72 
LDLR NM_000527 4.06 4.92 2.18 
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qRT-PCR:  
Data obtained by microarray analysis were verified by qRT-PCR for IGFBP1 (insulin-like 
growth factor-binding protein 1), HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), 
HMOX1 (heme oxygenase (decycling) 1 and EDN1 (endothelin 1) (fig. 18). Results of qRT-
PCR displayed minor differences in fold changes, but confirmed the results obtained by 
microarray analysis.  
 
Fig. 18: Fold changes of gene expression measured with microarray and 
qRT-PCR. Data obtained with qRT-PCR were normalized to GAPDH and 
set into relation to the solvent control (IGFBP1: insulin-like growth factor-
binding protein 1, HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase, 
HMOX1: heme oxygenase (decycling) 1, EDN1: endothelin 1). 
4.5 Discussion 
There is a high interest in the investigation of Cimicifugae racemosae rhizoma with different 
compositions of constituents and the correlation to their functional activity since the 
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components responsible for the pharmacological activity of Cimicifugae racemosae rhizoma 
so far have not been finally identified. 
Indeed, the extraction solvents used in the present study showed an impact on the 
composition of the different extracts, which was generally shown by 1H-NMR analysis and 
the content of triterpene glycosides investigated by HPLC. The spectra obtained by 1H-NMR 
indicated that various sets of constituents were extracted suggesting to include triterpene 
glycosides, phenylpropanoids and flavonoids. Therefore, the correlation of the functional 
activity to the chemical profile has to be considered for the whole extract and not exclusively 
for the amount of triterpene glycosides.  
In the present study, different extracts of Cimicifugae racemosae rhizoma exhibited different 
effects on cell proliferation. For actein an IC50 value of 27 µg/ml was reported for HepG2 cells 
(Einbond L., 2009) and 5.7 µg/ml in MDA-MB-453 after 96 hours of exposure (Einbond L., 
2008). In the human breast cancer cell MDA-MB-453 it was shown that the inhibitory effects 
on cell proliferation was primarily due to the triterpenes glycosides (Einbond L., 2008). The 
results obtained in the present study demonstrated the strongest antiproliferative effects for 
the ethanolic extract (61% of relative cell proliferation after six h). For this extract the highest 
amount of triterpenes was obtained (6.1 mg/ml). The less triterpene glycosides were 
extracted in the different extracts the less antiproliferative effects were observed. But the 1H-
NMR spectra of the dichloromethane and the ethanolic Cimicifugae racemosae rhizoma 
extracts displayed additional signals attributable to phenylpropanoids and flavonoids. 
Regarding toxicity mediated by Cimicifugae racemosae rhizoma, triterpene glycosides and 
also cinnamic acid esters were previously investigated for their apoptosis-inducing properties 
indicating that both natural products contribute to apoptotic effects (Hostanska K., 2004a; 
Hostanska K., 2004b). Hence, it can be suggested that the antiproliferative effects observed 
in the present study were not exclusively attributable to triterpene glycosides.  
In order to identify putative mechanisms in HepG2 cells treated with preparations from 
Cimicifugae racemosae rhizoma, genome-wide transcriptional alterations were investigated. 
One of the major findings of the microarray analysis was the influence on expression of 
genes related to cholesterol biosynthesis upon the treatment with the different extracts. 
There are several reports on the ability of Cimicifugae racemosae rhizoma or isolated 
compounds thereof to affect lipid synthesis. On the level of transcriptomics, a Cimicifugae 
racemosae rhizoma extract with a concentration of 40 µg/ml (total triterpene content 10.53%, 
about 3.8 µg/ml triterpenes) mediated alterations on cholesterol biosynthesis in MCF7 breast 
cancer cells (Einbond L., 2007). In rats actein was applied as a pure compound (35.7 mg/kg). 
There, it was shown that genes related to cholesterol and fatty acid biosynthesis as well as a 
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statin-related response was observed (Einbond L., 2009). In rats which were fed with 35.7 
mg kg-1 Cimicifugae racemosae extract (enriched with triterpenes, 27% triterpene glycosides, 
about 9.6 mg kg-1 total triterpene glycosides) it was observed that the cholesterol 
biosynthesis was altered on the transcriptomics level. The content of free fatty acids and 
triglycerides increased in the liver and decreased in the serum (Einbond L., 2012). In a 
clinical trial investigating a combination of Cimicifugae racemosae rhizoma (0.0364 ml, 
equivalent to 1 mg triterpene glycosides) and Hypericum perforatum (84 mg dried extract, 
equivalent to 0.25 mg hypericine) HLD-C serum levels increased (Chung D., 2007). 
Furthermore, it was reported that the fraction containing saponins (2.05 mg/day/animal) 
prepared from a Cimicifugae racemosae rhizoma extract was responsible for the reduction of 
cholesterol levels (Seidlova-Wuttke D., 2012). However, in a clinical study on 
perimenopausal and postmenopausal women no effects on the level of serum cholesterol 
were found after twelve months of administration of an ethanolic extract of Cimicifugae 
racemosae rhizoma (128 mg/d standardized to 7.27 mg triterpene glycosides) (Geller S., 
2009). 
Additionally, with respect to liver-toxic effects, liver and kidney necrosis related to cell death 
were induced by exposure to the ethanolic and dichloromethane extract. It was reported that 
Cimicifugae racemosae rhizoma extracts with a dose of 1,000 mg kg-1 (total triterpene 
content ≥ 6%, about 60 mg kg-1 per day of triterpenes) caused liver-toxic effects in rats 
evidenced by microvesicular steatosis (Lüde S., 2007). A Cimicifuga extract applied to rats at 
a dose of 300 mg kg-1 (total triterpene content 2.5%, about 7.5 mg kg-1 per day of triterpenes) 
did not affect liver morphology or liver function indices (Mazzanti G., 2008). The outcome of a 
study investigating liver-toxic effects indicated the involvement of mitochondrial toxicity. The 
mitochondrial membrane potential was decreased in HepG2 cells after exposure to a 
Cimicifugae racemosae rhizoma extract with a total triterpene content about 6 µg/ml (≥ 100 
µg/ml, total triterpene content ≥ 6%) (Lüde S., 2007). In the present study, microarray results 
obtained by IPA indicated that mitochondria and mitochondrial membranes depolarized in 
HepG2 cells after exposure of the ethanolic (total triterpene content about 12.2 µg/ml) and 
dichloromethane extract (total triterpene content about 8.8 µg/ml).  
The microarray results in this study showed a lot of similar cellular effects for the 
dichloromethane and ethanolic extract, e. g. responses affecting cholesterol biosynthesis or 
mitochondrial stress responses. These effects were not observed after exposure to the 
ethanolic 50% (V/V) extract. A major difference between the ethanolic and dichloromethane 
extract was the expression of genes related to cytochromes. The gene expression profile of 
cells exposed to the ethanolic and ethanolic 50% (V/V) extract showed the induction of 
genes related to the “Cytochrome P450 Panel-Substrate is an Eicosanoid”. Exclusively for 
the ethanolic extract the signal cascade “Cytochrome P450 Panel-Substrate is a Fatty Acid” 
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was significantly activated. Thereby, it can be assumed that phytochemical compounds 
influencing induction of cytochromes were extracted using ethanol. In previous studies it was 
shown that preparations of Cimicifugae racemosae rhizoma changed the activities of 
CYP1A2, CYP2B CYP2C9, CYP3A and CYP2D6 (Huang Y., 2010; Yokotani K., 2013). It 
was demonstrated that the relevant extract inhibited the activity of cytochromes, but it was 
also shown that pure compounds like cimicifugic acid a and b and especially fukinolic acid 
inhibited cytochrome activity even stronger (Huang Y., 2010). In the present study the 
respective cytochromes were not altered at the transcriptional level; however, extracts were 
prepared with different solvents. The results emphasize the impact of various secondary 
metabolites on the activity of cytochromes. 
Conclusively, the results of the present study demonstrated that the metabolomics approach 
investigated in this study is an efficient technique to comprehensively investigate the 
phytochemical fingerprint of herbal extracts and to complement established methods for the 
characterization of herbal preparations. With regard to the extraction solvents, extracts with 
differing extract compositions were obtained. At the transcriptional level, several effects were 
observed in common for extracts with a similar composition of components. But even for 
these extracts relevant differences were obtained, like a differential induction of genes 
related to cytochromes. The present study supports the importance of appropriate quality 
assurance and characterization of herbal preparations. The comprehensive investigation of 
herbal substances and preparations thereof by metabolomic and transcriptomic analyses are 
meaningful; the application of these techniques for regulatory affairs has to be examined with 
further research.  
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5 Differential transcriptional profiles mediated by exposure to 
silybin and a preparation derived of Silybi mariani fructus  
5.1 Abstract 
Objective: Milk thistle is an medicinal plant that originates from the Mediterranean region. 
Based on traditional use, milk thistle has been used as an herbal remedy, especially for 
diseases related to the liver and the gallbladder. Several studies suggest that silymarin 
protects the liver from toxins and that these flavonolignans exhibit anti-oxidative and anti-
inflammatory activity.  
Materials and Methods: In the study presented, Silybi mariani fructus was extracted (70% 
(V/V) ethanol) and chemically characterized by means of 1H-NMR analysis and quantification 
of silymarin with RP-HPLC-DAD. The cell proliferation rate was investigated after exposure 
to the 70% (V/V) ethanolic Silybi mariani fructus extract and silybin as a pure substance. 
Gene expression profiling (Whole Genome Gene Expression Microarrays v2, Agilent 
Technologies) was analyzed for both conditions (5 replicates each).  
Results: 1H-NMR analysis suggested that various groups of constituents, such as organic 
acids, amino acids, glycosides, and aromatic compounds, were present in the Silybi mariani 
fructus extract. The quantification of silymarin showed a content of 4.8 mg/ml. HepG2 cells 
were exposed to the extract corresponding to a concentration of 9.6 µg/ml silymarin. Silybin 
as a chemically-defined substance was applied in a concentration of 9.6 µg/ml. The cell 
proliferation did not exhibit significant differences in relation to vehicle control. Gene 
expression profiling revealed different cellular responses. Silybin altered signal cascades 
related to cell death, proliferation, and development, while the molecular and cellular 
functions affected by Silybi mariani fructus were related to drug metabolism, cell morphology, 
and cellular assembly and organization. Common to both conditions, signal cascades 
associated with lipid metabolism and small molecule biochemistry were activated. 
Furthermore, microarray data evaluation demonstrated the involvement of liver-toxic 
pathways common to both conditions, such as liver damage and liver regeneration. However, 
liver necrosis and liver cholestasis were altered exclusively after exposure to silybin. The 
exposure of HepG2 cells to Silybi mariani fructus activated the signal cascades liver fibrosis 
and glutathione depletion, which was not observed for cells exposed to silybin. 
The expression of the solute carrier transporters SLC16A6, SLC24A4, and SLC7A11 was 
changed suggesting a putative role in drug resistance. 
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Conclusion: Although cell proliferation was basically not affected by silybin or Silybi mariani 
fructus extract, microarray data evaluation revealed differently activated cellular 
mechanisms. This emphasizes that cellular responses after application of multicomponent 
mixtures may differ widely from isolated substances thereof, and the appropriate 
characterization of herbal extracts is highly important.  
 
Gene abbreviations 
AhRR: Aryl-hydrocarbon receptor repressor; CYP1A1: Cytochrome P450 family 1 member 
A1; Cyp1B1: Cytochrome P450 family 1 member B1; SLC7A11: Solute Carrier Family 7, 
Member 11; SLC16A6: Solute Carrier Family 16, Member 6; SLC24A4: Solute Carrier Family 
24, Member 4; SOS1: Son of sevenless homolog 1; TGF β: Transforming growth factor β 
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5.2 Introduction 
Herbal medicines are frequently used worldwide and their use in Europe is increasing 
(Jordan S., 2010). People from various nations rely on medicinal plants for their primary 
health care. In phytotherapy, therapeutic efficacy is based on the combined action of a 
mixture of constituents. The secondary metabolites produced by the plant act in various 
ways; the pharmaceutical effects may be exhibited by the synergistic or antagonistic 
interaction of many phytochemicals. Omics-technologies and systems biology may facilitate 
elucidating synergistic effects of herbal mixtures. 
The mature fruits of Silybum marianum (L.) Gaertn. (Asteraceae) and preparations thereof 
have been marketed for several decades. The constituent described to be responsible for 
their pharmacological activity is silymarin (Flora K., 1998; van Erp N., 2005; Polyak S., 2010). 
Silybin, silychristin, silydianin and isosilybin are the main flavonolignan components of 
silymarin (fig. 19). 
 
Silybin 
 
Silidianin 
  
Silichristin 
 
Fig. 19: Structure of typical flavonolignans in 
Silybi mariani fructus.  
Within the fruit of the plant flavonoids such as dihydrokaempferol and taxifolin have been 
identified as well as sterols (cholesterol, campesterol and stigmasterol) (Abenavoli L., 2010). 
The content of lipids is high, in a range of 20-30% linoleic acid, oleic acid, and palmic acid 
have been identified. As further constituents, saponins, amines, sugars, and mucilages have 
been isolated from Silybi mariani fructus (Abenavoli L., 2010; Wagner H., 1974).  
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In the European Pharmacopeia 8.0, “Milk Thistle fruit” (01/2014:1860) and the herbal 
preparation “Milk Thistle dry extract, refined and standardized” (01/2014:2071) are 
monographed. For the fruit, a content of at least 1.5% silymarin is specified. 
Silybi mariani fructus has been traditionally used, and Commission E monograph described 
its use against toxic liver damage, liver diseases, and chronic inflammatory liver diseases. 
Furthermore, Silybi mariani fructus has been traditionally used for treatment of the spleen 
and, gallbladder for ailments such as jaundice and gallbladder colic. In Germany, silybin has 
been approved for the treatment of Amanita phalloides poisoning (Wellington K., 2001). 
The potential benefit of Silybi mariani fructus in health care for liver diseases still remains a 
controversial issue. Regarding safety of Silybi mariani fructus, there are no reports on 
adverse side effects.  
Several reports suggest antioxidant, anticancer, hepato- and nephroprotective activity for 
Silybi mariani fructus. Silymarin is described as protecting against various chemicals and 
toxicants like lasalocid, irradiation, carbon tetrachloride, ethanol, and paracetamol (van Pelt 
J., 2003; Cho B., 2013; Garrido A., 1991; Radko L., 2013). The proposed mechanism of 
action is associated with the antioxidant function (Valenzuela A, 1986), inhibition of lipid 
peroxidation and scavenging of free radicals (Gyorgy I., 1992; Mira L., 1994), which may 
stabilize the membrane. Associated with cellular regeneration, silymarin has been shown to 
stimulate RNA polymerase I, leading to an increase in the protein synthetic apparatus and a 
higher turnover of structural and functional proteins (Machicao F., 1977). Furthermore, 
silymarin has shown protective effects via an increase in total glutathione content and 
glutathione-related enzymes (Valenzuela A., 1989).  
The objective of this study was to evaluate cellular responses after exposure to a complex 
herbal extract of Silybi mariani fructus and the chemically-defined substance silybin. Contrary 
to the investigated herbal substances Chelidonii herba and Cimicifugae racemosae rhizoma 
described in chapter 3 and 4, Silybi mariani fructus is not considered to be liver-toxic. Hence, 
Silybi mariani fructus represented an interesting model object for evaluation of gene 
expression analysis. Silybi mariani fructus was extracted with 70% (V/V) ethanol. This 
solvent is frequently used in the preparation of commercially available preparations 
containing Silybi mariani fructus. The extract was investigated with 1H-NMR analysis, as it 
has been shown to be a useful method for comprehensive characterization of complex herbal 
mixtures (Daniel C., 2008). Additionally, the silymarin content was quantified with RP-HPLC-
DAD. For the investigation of cellular effects, HepG2 liver cells were used. Functional tests, 
including the analyses of the cell proliferation rate and gene expression profiling, were 
60 
performed to characterize cellular responses after exposure to the complex Silybi mariani 
extract and silybin, respectively. 
5.3 Materials and Methods 
Chemicals and reagents: 
Silybin (≥98% [HPLC]), containing both A and B diastereomers, was purchased from Sigma-
Aldrich (Hamburg, Germany). 
Plant material:  
The herbal substance was complying with the monograph European Pharmacopeia 8.0 “Milk 
Thistle fruit” (01/2014:1860). It was purchased from a local pharmacy and powdered by a 
mill. The sample material Silybi mariani fructus in analogy to voucher specimens was 
deposited at the Institute of Pharmaceutical Biology, University of Bonn. 
Extraction of Silybi mariani fructus: 
The plant material was powdered and 2.0 g were extracted with 20.0 ml of 70% (V/V) ethanol 
for 20 min. The extract was divided into two equal parts. The solvent was evaporated using a 
rotary evaporator, respectively. For 1H-NMR measurement and HepG2 cells experiments, the 
residue was solubilized in 1.0 ml deuterated DMSO-d6. For the quantification of silymarin by 
HPLC, the dried extract was solubilized in 5 ml 50% (V/V) methanol.  
Quantification of silymarin in Silybi mariani fructus extract: 
Silymarin in the 70% (V/V) ethanolic Silybi mariani fructus extract was analyzed with RP-
HPLC-DAD at wavelength 288 nm using DAD. The HPLC system was equipped with an 
1100 quaternary pump, 1100 autosampler, 1100 column thermostat, and 1100 diode array 
detector (all components from Agilent Technologies).  
With respect to the quantification of silymarin a validated method described in the European 
Pharmacopeia was used. Regarding validation based on ICH guideline, linearity, precision of 
the instrument, precision of the method and limit of detection was determined (International 
Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, 2005). The determination of linearity indicated R2=1 after 
injection of silybin A and B in a range or 219.5 to 10.97 µg/ml. Precision of the instrument 
showed a relative standard deviation of 0.12% and 0.28% for silybin A and B, respectively. 
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Precision of the method showed a relative standard deviation of 8.22% after injection of six 
replicates of 70% (V/V) ethanolic Silybi mariani fructus extract (two injections of the extract). 
The lower limit of detection was 0.1 µg/ml for silybin A and B. 10µl of the extract used for 
quantification was injected twice.  
Peaks corresponding to silymarin within the chromatogram were identified according to the 
monograph: “Milk thistle dry extract, refined and standardized” using the reference “milk 
thistle dry extract HRS” from the EDQM (Strasbourg, France). The chromatogram obtained 
for the 70% (V/V) ethanolic Silybi mariani fructus did not show major variation in retention 
times compared to the reference chromatogram from EDQM. Quantification of silymarin was 
performed with silybin (A+B) standard (Sigma-Aldrich, Hamburg, Germany). The peak 
identity of silidianin was confirmed with spike experiments with silidianin (PhytoLab GmbH & 
Co. KG, Vestenbergsgreuth, Germany).  
The extracts were filtered via 45 µm membranes. For the separation of silymarin Luna C18 
(150x4.6 mm,3 µm) (Phenomenex, Aschaffenburg, Germany), columns with a cartridge 
(SecurityGuard cartridges for C18 HPLC with 3.0 µM inner diameter) were used. The solvents 
(solvent A: phosphoric acid, methanol, water [0.5:30:70]; solvent B, phosphoric acid, 
methanol, water [0.5:80:20]) were used in a gradient with a flow of 1.0 ml/min. Separations 
were effected by a series of linear gradients of solvent B into solvent A as follows: elution 
starting with 12.0-20.0% B in A, 0-10 min; 20.0-25.0% B in A, 10-15 min; 25-40% B in A, 15-
30 min; 40-75% B in A, 30-35 min; 75-100% B in A, 35-40 min;100-12% B in A, 40-25 min; 
12% B in A 45-50 min. 
1H-Nuclear magnetic resonance (NMR) spectroscopy: 
1H-NMR spectra of extracts were recorded with a Bruker advance 300 DPX instrument 
(temperature 25 °C, 64 scans). Calibration of spectra was performed according to signals of 
incomplete deuterated solvents (DMSO [2.54 ppm]). Data from δ 0 to δ 10 ppm were 
considered for the analysis of 1H-NMR fingerprint.  
Preparation of total RNA: 
Total RNA was isolated from HepG2 cells using RNeasy Mini Kit (Qiagen, Germany) 
following the manufacturer’s instructions.  
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Whole genome microarray: 
The concentration and purity of extracted RNA was measured using an UV-visible 
spectrometer (NanoDrop 1000; Thermo Fisher Scientific, Waltham, MA) by absorption at 
wavelengths of 260 and 280 nm. RNA samples with a 260/280 nm absorption ratio > 1.8 and 
RIN > 9.5 were used in subsequent microarray analysis. For microarray profiles, 
fluorescently labeled cRNA samples were prepared from 100 ng RNA using reverse 
transcriptase. The amplification reaction with simultaneous introduction of Cy3-dCTP to the 
amplified complementary RNA (cRNA) was performed using a Quick Amp Labeling Kit for 
One-Color labeling (Agilent Technologies). The concentration of the purified samples and the 
Cy3 dye incorporation efficiency was evaluated using a NanoDrop 1000 spectrophotometer. 
After fragmentation (60 °C, 30 min), the single colour cRNA samples were hybridized to a 
DNA chip (Whole Genome Gene Expression Microarrays v2, Agilent Technologies, 8x60K, 
27,958 Gene RNAs, 7,419 lincRNAs) at 65 °C for 17 hours in a hybridization oven (Agilent 
Technologies). Five independent experiments were performed under each experimental 
condition.  
qRT-PCR: 
After reverse transcription by random priming the resulting cDNA was used for qRT-PCR. 
Following initial denaturation (95 °C, 10 min), amplification was performed over 45 cycles 
(Light Cycler 480, Roche) with denaturation at 95 °C for 10 s. Primers with the respective 
annealing temperature are shown in tab. 7. Elongation was performed at 72 °C for 20 s. The 
size of PCR fragments was analyzed by agarose gel electrophoresis. Gene expression was 
evaluated with Light Cycler 480 Software 1.5 and Cp-values were normalized to GAPDH. 
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Data processing and statistics: 
Hybridized DNA chip slides were scanned using an Agilent Scanner (Agilent Technologies) 
with Feature Extraction Software (Agilent Technologies). Fluorescence intensity data were 
imported to GeneSpring GX version 12.5 (Agilent Technologies) with the quantile scaling 
normalization.  
Light intensities were filtered to exclude low-quality data to guarantee the accuracy of the 
statistical analysis. Spots with lower intensities than the threshold, which was determined 
based on the intensities of the Agilent RNA Spike-Mix, were filtered to exclude spots weaker 
than background noise. Spots with saturated intensities and near-background intensities 
were excluded. The final filtration was conducted based on the fold increase. Statistical 
analysis of the remaining genes was performed with a t-test corrected using the Benjamini 
and Hochberg false discovery rate (Benjamini Y., 1995). Genes were considered as up- or 
down-regulated with a fold ≥ 2, ≤ -2, and p < 0.05.  
Tab. 7: Primer used for qRT-PCR for validation of microarray results. 
Primer/ 
Gene 
name 
NCBI 
accession 
code 
Primer sequence (5´→´3´) 
Annealing 
temperature 
(°C) 
AhRR_1 NM_020731 CAGTTACCTCCGGGTGAAGA 59 
AhRR_2 NM_020731 CCAGAGCAAAGCCATTAAGA 59 
Cyp1A1_1 NM_000499.3 AACCTTTGAGAAGGGCCACA 55 
Cyp1A1_2 NM_000499.3 GACCTGCCAATCACTGTGTC 55 
Cyp1B1_1 NM_000104 CACTGCCAACACCTCTGTCTT 53 
Cyp1B1_2 NM_000104 CAAGGAGCTCCATGGACTCT 53 
GAPDH_1 NM_002046.4 CCACCCATGGCAAATTCCATGGCA 57 
GAPDH_2 NM_002046.4 CTAGACGGCAGGTCAGGTCCACC 57 
SOS1_1 NM_005633 GAGTGAATCTGCATGTCGGTT 57 
SOS1_1 NM_005633 CTCTCATGTTTGGCTCCTACAC   57 
 
64 
These processed data were used for further analysis by Ingenuity Systems Inc. Reedwood 
City, USA (Qiagen). Ingenuity data base was used as reference set. In the networks 
interaction 70 molecules and all data sources were integrated in data analysis. Data were 
compared to the human reference data. 
Treatment of HepG2 cells with plant extracts: 
HepG2 cells were purchased from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures GmbH and were used between passage 3 and 12. The 
cells were maintained in T75 flasks in RPMI 1640 medium supplemented with 10% fetal 
bovine serum, 1% penicillin/streptomycin solution (100 U/ml) and 1% L-glutamine. The cells 
were constantly incubated in humidified atmosphere at 5% CO2 and 37 °C. 
When the cells were about 80% confluent, they were exposed to trypsin and harvested by 
centrifugation. Subsequently, they were counted and an equal number of cells (1.0 x 106 
cells/5 ml media) was transferred to each experimental plate (5 cm Ø). For treatment on the 
following day medium containing Silybi mariani fructus extract and silybin (9.6 µg/ml), each 
adjusted to 1% DMSO were applied to the liver cells, respectively. Cells were exposed to the 
extract in a concentration of 1:501 (9.6 µg/ml silymarin). The vehicle treated cells (1% 
DMSO) served as control group. Five replicates were performed for each experimental 
condition for microarray investigations.  
Cell growth and proliferation assay using xCELLigence system: 
About 7500 HepG2 cells were seeded to each well. After 24 h, medium containing the extract 
in a concentration of 1:501, or silybin (9.6 µg/ml), each adjusted to 1% DMSO was added, 
respectively. As solvent control medium containing 1% DMSO was applied. The cell index 
was monitored every 15 min.  
5.4 Results 
1H NMR analysis: 
The 70% (V/V) ethanolic Silybi mariani fructus extract was subjected to 1H-NMR analysis. 
The spectrum (fig. 20) showed a signal from water (δ 3 to δ 6 ppm), but this signal did not 
interfere with the evaluation of important groups of metabolites. The signals near to the 
signal of water may be attributed to metabolites such as primarily saccharides and amino 
acids. In the spectrum of the Silybi mariani fructus extract, intense signals in the region of 
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δ 0.5 to δ 2.5 ppm were assigned. Protons attached to organic acids such as fatty acids 
resonate in this region. The remaining part (δ 5.5-δ 10.0 ppm) is considered to be the 
aromatic region, which contained various smaller signals. Protons attached to flavonoids, 
flavonolignans and phenolics resonate in the region from δ 5.5-δ 7.5 ppm. Several signals 
were observed in this region. 1H-NMR resonances for alkaloids were expected in the 
downfield region (δ 7.5 to 10 ppm). Only smaller signals associated with this region were 
observed.  
 
 
Fig. 20: 
1
H-NMR spectrum of 70% (V/V) ethanolic Silybi mariani fructus extract. The 
spectrum was analyzed in DMSO-d6. 
Quantification of silymarin in Silybi mariani fructus extract:  
The content of silymarin was quantified in the extract with RP-HPLC-DAD (288 nm) (tab. 8).  
7.50 5.00 2.50
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Tab. 8: Quantified silymarin in the 70% (V/V) ethanolic Silybi 
mariani fructus extract.  
 
 Extract (mg/ml) 
Silicristin 0.7 
Silidianin 1.5 
Silybin A 0.7 
Silybin B 1.0 
Isosilybin A 0.6 
Isosilybin B 0.3 
Total silymarin 4.8 
In the extract, a total silymarin content of 4.8 mg/ml (9.6 mg/g dry weight) was determined. 
According to the monograph of the European Pharmacopeia “Milk thistle dry extract, refined 
and standardized”, the percentage content of silicristin and silidianin was 46%, with reference 
to total silymarin. The percentage content of silybin A and silybin B was 35%, 19% for 
isosilybin A and isosilybin B with reference to total silymarin, respectively.  
 
Cell proliferation of HepG2 cells: 
Proliferation of HepG2 cells was investigated after exposure to 70% (V/V) ethanolic extract of 
Silybi mariani fructus (9.6 µg/ml silymarin) and silybin (9.6 µg/ml) as an isolated constituent 
thereof, each adjusted to 1% DMSO, respectively. The relative cell proliferation of HepG2 
cells (fig. 21) was basically not affected due to exposure to the Silybi mariani fructus extract 
and silybin.  
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Fig. 21: Cell proliferation of HepG2 liver cells after exposure to 70% (V/V) Silybi 
mariani fructus extract and silybin, respectively. Cell proliferation was set into 
relation to the control and treatment start. The Silybi mariani fructus extract 
(silymarin 9.6 µg/ml) and silybin (9.6 µg/ml) were applied to the cells. Values are 
expressed as the mean ±SEM of at least 4 to 6 replicates. 
Gene expression profiling of HepG2 cells after exposure to 70% (V/V) ethanolic Silybi 
mariani fructus extract and silybin: 
The cellular transcription profile was investigated six hours after exposure to silybin and 70% 
(V/V) ethanolic Silybi mariani fructus extract. Data evaluation with Genespring 12.5 revealed 
148 altered biological entities after exposure to silybin and 161 after exposure to the herbal 
preparation, respectively. 
The significantly regulated genes were further analyzed with IPA to investigate significantly 
altered signal cascades. The molecular and cellular functions affected exclusively by Silybi 
mariani fructus extract were “Drug Metabolism, Cell Morphology, Cellular Assembly, and 
Organization”. The signal cascades “Lipid Metabolism” and “Small Molecule Biochemistry” 
were altered by both Silybi mariani fructus and silybin. The signal cascades “Cell Death and 
Survival, Cellular Development and Cellular Growth and Proliferation” were altered by 
exposure to silybin. 
Signal cascades related to toxicities indicated that different processes had been altered (fig. 
22). The exposure to silybin changed pathways involved in the damage of mitochondria 
(“Increases Permeability Transition of Mitochondria and Mitochondrial Membrane, Increases 
Damage of Mitochondria, Increases Depolarization of Mitochondria and Mitochondrial 
Membrane”) and “TGF-β-Signaling”. Furthermore, signal cascades such as “Hepatic Stellate 
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Cell Activation” and “Increases Liver Hepatitis” were activated by the exposure to silybin. 
Processes related to biotransformation and drug metabolism were also altered differently. 
Exposure to silybin induced changes in “PXR/RXR Activation” and “Cytochrome P450 Panel-
Substrate is a Vitamin”, while exposure to the Silybi mariani fructus extract induced the signal 
cascades “Aryl Hydrocarbon Receptor Signaling, Xenobiotic Metabolism Signaling, Fatty 
Acid Metabolism, Cytochrome P450 Panel-Substrate is a Sterol” and “Cytochrome P450 
Panel-Substrate is a Xenobiotic”.  
Hepatotoxicity-associated signal cascades were also affected differently by the Silybi mariani 
fructus extract and the pure compound silybin. The signal cascades “Liver Necrosis” and 
“Liver Cholestasis” were exclusively induced after exposure to silybin. The complex extract 
exclusively changed “Liver Hyperplasia/Hyperproliferation, Liver Fibrosis” and “Glutathione 
Depletion in Liver”. In common to both conditions, the signal cascades “Liver Damage, Liver 
Inflammation/Hepatitis, and Liver Regeneration” were affected.  
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Fig. 22: Signal cascades involved in liver toxicity (upper part), related to metabolism 
(middle part) and liver-toxic diseases (lower part) in HepG2 cells after exposure to 
silybin (9.6 µg/ml) and 70% (V/V) ethanolic Silybi mariani fructus extract (9.6 µg/ml 
silymarin), respectively. The data were obtained with IPA data evaluation. Dark blue 
color: treatment with silybin; light blue color: treatment with 70% (V/V) ethanolic 
Silybi mariani fructus extract. Effects were considered statistically significant, if 
values were exceeding a threshold of p > -log 1.31. 
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Transcriptional regulation of SLC transporters:  
Gene expression of solute carrier transporters was investigated more in detail (tab. 9).  
Tab. 9: Relative quantities of solute carrier transporters mRNA 
expression. Data are shown as a fold change and obtained by 
microarray analysis. HepG2 cells were exposed to 70% (V/V) Silybi 
mariani fructus extract (silymarin: 9.6 µg/ml) and silybin (9.6 µg/ml). 
 
 Silybi mariani fructus Silybin 
SLC16A6 4.22 3.44 
SLC24A4 -2.95  
SLC7A11  2.84 
It was shown that three different transporters were significantly regulated for at least one 
condition. Solute carrier family 16 member A6 (SLC16A6) was upregulated for both 
conditions. Solute carrier family 24 member A4 (SLC24A4) was downregulated after 
exposure to Silybi mariani fructus. Exposure to silybin induced the gene expression of solute 
carrier family 7 member A4 (SLC7A4).  
qRT-PCR: 
Data obtained by microarray were verified by qRT-PCR for selected genes (fig. 23). Results 
of qRT-PCR displayed minor differences in fold changes but confirmed the results obtained 
by microarray analysis. 
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Fig. 23: Fold changes in gene expression measured with microarray and qRT-PCR. 
Data obtained with qRT-PCR were normalized to GAPDH and set into relation to the 
solvent control (AhRR: aryl-hydrocarbon receptor repressor, Cyp1A1: Cytochrome 
P450 family 1 member A1, Cyp1B1: Cytochrome P450 family 1 member B1, SOS1: Son 
of sevenless homolog 1) * means statistically not significant. 
5.5 Discussion 
The complexity of the Silybi mariani fructus extracts was demonstrated in the 1H-NMR profile. 
According to the signals obtained in the 1H-NMR spectrum, it can be suggested that 
phytochemical constituents like terpenoids, steroids, sugars, flavonoids and flavonolignans 
were extracted. Moreover, it was demonstrated with RP-HPLC-DAD that silymarin in a 
concentration of 4.8 mg/ml was obtained in the extract.  
Cellular effects of Silybi mariani fructus and silybin were investigated. A corresponding 
concentration of silymarin and silybin was applied to HepG2 cells, respectively (9.6 µg/ml 
silymarin in the Silybi mariani fructus extract, 9.6 µg/ml silybin as a pure compound).  
Investigations of HepG2 cell proliferation indicated no major antiproliferative effects for either 
condition. Previous studies have suggested an IC50 value of 150 µg/ml after 24 hours of 
exposure in HepG2 cells (Ashtiani H., 2013; Vakili M., 2012). Since the cell proliferation rate 
of HepG2 cells exposed to silybin and the Silybi mariani fructus extract did not display major 
differences, it can be suggested that the extracted constituents, aside from silymarin, did not 
exhibit antiproliferative effects. 
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Transcriptomics-based investigations were performed in this study, as it had already been 
shown that gene expression profiling may be beneficial for the understanding of the 
underlying mechanisms of phytopharmaceuticals (Ulrich-Merzenich G., 2007).  
Associated with toxicities, the impairment of mitochondria in HepG2 cells after exposure to 
silybin were indicated by microarray experiments. The increase in the mitochondrial-
permeability transition is a mechanism that causes mitochondrial failure, which can lead to 
necrosis from ATP depletion or caspase-dependent apoptosis if ATP depletion does not fully 
occur (Jaeschke H., 2002; Piret J., 2004).  
Furthermore, exposure of HepG2 cells to silybin led to the activation of the transforming 
growth factor β (TGF-β) signaling, and TGF-β was significantly downregulated under this 
condition (data not shown). In earlier studies, it had already been demonstrated that 
silymarin influenced the expression of TGF-β (Jeong D., 2005; Jia J., 2001; Kim S., 2009). 
TGF-β has various functions and plays a role in growth, differentiation, apoptosis and tissue 
homeostasis (Massague J., 1998), but it has also been shown that alterations in the TGF-β 
expression are also involved in hepatoprotective effects (He Q., 2002). Previous studies with 
mast cells supported that silymarin has shown anti-fibrotic and anti-inflammatory effects 
associated with the activation of hepatic stellate cells through the regulation of TGF-β (Jeong 
D.H., 2005). Hepatic stellate cells may be activated by hepatotoxins thus eventually leading 
to liver fibrosis.  
One of the major findings of microarray analysis was the differential expression of 
biotransformation enzymes upon exposure of HepG2 cells to the Silybi mariani fructus 
extract and silybin. In this study, the aryl hydrocarbon receptor (AhR) was involved in signal 
cascades upon exposure to Silybi mariani fructus extract. AhR is a transcription factor that 
plays a role in the transcriptional regulation of several key enzymes involved in the 
metabolism of xenobiotic substances. This transcription factor can be activated by a wide 
range of herbal compounds, such as flavonoids, alkaloids, phenols and catechins (Denison 
M., 2003). Subsequently, from the results obtained in the present study, it can be suggested 
that mRNA expression of the cytochrome P450s CYP1A1 and CYP1B1 may be regulated by 
AhR. Despite the role in the biotransformation of AhR, it further functions in many cellular 
processes, like cell growth, apoptosis, cell adhesion, immune responses and cell matrix 
metabolism (Puga A., 2009; Vogel C., 2014).  
Previous investigations have indicated that silymarin has inhibited the activity of cytochrome 
P450 CYPA1, CYP2E1 and CYP2D6 (Dvorak Z., 2006a; Kiruthiga P., 2013; Zuber R., 2002). 
In this regard, the induction of Cyp1A1 was obtained for HepG2 cells exposed to Silybi 
mariani fructus extract based on the transcriptional level. 
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Interestingly, exposure to silybin as a chemically-defined substance activated the pregnane X 
receptor/retinoid X receptor (PXR/RXR) signal cascade, which was not achieved after 
exposure to Silybi mariani fructus extract. PXR in conjunction with RXR display receptors 
with a central role in drug metabolism. Various phytochemicals and clinical drugs are 
metabolized by the cytochrome P450 CYP3A4, which is inducible with PXR/RXR 
heterodimer receptors. Additional important roles of PXR/RXR are associated with drug 
efflux pumps, lipid metabolism and the excretion synthesis and metabolism of bile acid 
(Moreau A., 2008; Schuetz E., 2001; Teng S., 2003). Thus, various important physiological 
and protective functions are assignable to PXR/RXR. Interestingly, PXR/RXR was shown to 
be involved in the expression of the organic anion transporting polypeptide 2 (Oatp2) 
(Staudinger J., 2001), which is suggested to be involved in the antidote action of silymarin 
after Amanita phalloides poisoning (Fehrenbach T., 2003). A possible role of silybin for the 
PXR and the induction of cytochrome P450 CYP3A4 has been described previously (Dvorak 
Z., 2006a; Xie Y., 2013), supporting the PXR response obtained in the current study.  
The biotransformation of silybin and Silybi mariani fructus indicated that the multicomponent 
mixture activated more and different genes associated with xenobiotic metabolism. 
According to the results of cytochrome P450s CYP1A1 and CYP1B1, it can be concluded 
that the induction is primarily not received by silybin, but rather by other secondary 
metabolites of the Silybi mariani fructus extract.  
In Germany, silybin is approved for the treatment of Amanita phalloides poisoning. The meta-
analysis of clinical data has encouraged the supportive therapy of silymarin for this indication 
(Saller R., 2008). For the toxin blockade of silymarin, it has been suggested that SLC 
transporters (SLC21A6) may be involved (Fehrenbach T., 2003). However, results described 
in previous studies have indicated that SCL21A6 is not present in HepG2 cells (Cui Y., 
2003). With regard to this finding, no alterations were shown for SLC21A6 on the 
transcriptional level in this study. Therefore, the expression of other SLC transporters in 
HepG2 cells exposed to the Silybi mariani fructus extract and silybin was investigated in the 
present study. The results obtained in the current study indicate the regulation of SLC16A6, 
SLC24A4 and SLC7A11. Previous studies have indicated a putative role of SLC16A6 and 
SLC7A11 in drug resistance (Januchowski R., 2013). Since ABC transporters may also play 
a role in this phenomenon, the microarray results of this study were screened for ABC 
transporter expression but showed no significant gene expression.  
The transferability of results obtained from in vitro experiments to in vivo experiments is 
challenging. The relevance of data obtained from in vitro experiments under controlled 
conditions for clinical practice has to be considered carefully. Results obtained with in vitro 
experiments may be beneficial for the first prediction of biotransformation and possible toxic 
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effects. Discrepancies between in vitro results and clinical studies have been observed, thus, 
the clinical relevance should always be proven in clinical trials (Goey A., 2013). Several 
reports describe the low bioavailability of silymarin; hence, it is difficult to estimate and 
assess the human-relevant concentration in plasma.  
Gene expression profiling and systems biology may facilitate the unravelling of the cellular 
and putative synergistic effects of herbal mixtures.  
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6 Interlaboratory comparison of microarray gene expression 
analyses of HepG2 cells exposed to different Chelidonii herba 
extracts 
6.1 Abstract 
Background: DNA/RNA microarray technologies are frequently applied to investigate 
transcriptional changes. The objective of the present study was the analysis of reproducibility 
and affected signal cascades of different Agilent microarray platforms performed in different 
laboratories. The herbal substance Chelidonii herba was used as a model. 
Materials and Methods: Identical samples, extracted in the same laboratory (BfArM) were 
used for microarray analysis. The labeling and hybridization procedure was performed 
according to a standardized procedure. In total, four replicates were used for each 
experimental condition and the vehicle control, respectively. Two different microarray 
platforms (SurePrint G3 Human Gene Expression 8x60K Microarray Kit [Miltenyi Biotec] and 
SurePrint G3 Human Gene Expression 8x60K v2 Microarray Kit [BfArM]) were used. The 
data were evaluated using Genespring 12.5 software (Agilent Technologies).  
Results: In total, 30,746 biological features were common for both microarray platforms. After 
exposure to a dichloromethane and an ethanolic Chelidonii herba extract, 150 and 211 
genes were significantly regulated represented for both microarray platforms, respectively. 
The gene expression profile revealed 108 and 35 significantly regulated genes in common 
for the ethanolic 50% (V/V) and the aqueous extract, respectively. Additionally, microarray 
analysis demonstrated regulated genes only for one microarray platform although they were 
represented for both microarray platforms. At least 64.4-86% thereof showed fold changes 
≤ 3 and ≥ -3. The comparison of common significantly regulated genes indicated less 
variability. Microarray data showed a quite good correlation of affected signal cascades. 
Discussion and Conclusion: The reproducibility of microarray is reasonable, especially for 
genes with fold changes ≥ 3 and ≤ -3. Because of a good correlation of affected signal 
cascades, it can be suggested that results obtained by microarray analysis can be applied for 
the comprehensive investigation of gene expression profiling. As some controversial gene 
regulations were observed, genes of special interest should be validated by qRT-PCR. 
Nevertheless, differences in the regulation of genes cannot be excluded. 
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6.2 Introduction 
Since the 1990s microarrays have emerged and their usage has continuously been 
enhanced. For DNA/RNA microarrays various applications are known, such as the analysis 
of gene expression (Afshari C., 2011; Brazhnik P., 2002; de la Fuente A., 2002; Fedorov A., 
2014; te Pas M., 2013; van Dyk E., 2014) or the detection of single nucleotide 
polymorphisms (SNPs) (Nguyen T., 2013). Protein Chips are used to reveal interactions or 
activities of proteins or to determine protein functions (Melton L., 2004). A specific form of a 
protein microarray is an antibody microarray used for diagnostic applications or to detect 
protein expressions (Rho J., 2013). Small-molecule microarrays have risen to areas ranging 
from protein profiling to the discovery of therapeutic leads (Uttamchandani M., 2005).  
Currently, different microarray platforms from different companies are commercially 
available. It is known that interlaboratory and interplatform differences may contribute to 
variability in evaluation of microarray data. Various researchers investigated the 
comparability of data obtained by the application of different platforms. Although variability in 
the microarray data obtained with different platforms and laboratories occurred, standardized 
protocols and data evaluation strategies reduced variability (Dobbin K., 2005; Dumur C., 
2008). 
The objective of the present study was an interlaboratory comparison with very similar 
platforms. RNA samples generated in the same laboratory were analyzed by different Agilent 
whole genome microarrays by different experimenters in our laboratory and at Miltenyi 
Biotec. Miltenyi Biotec is a company which commercially provided microarray services. Data 
from both laboratories were statistically evaluated using the same strategy.  
6.3 Materials and Methods 
Cell culture and exposure to the different Chelidonii herba extracts: 
HepG2 cells were cultivated as described before (chapter 3.3). 
RNA extraction: 
The isolation of total RNA was performed as described before (chapter 3.3). 
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Microarray labelling and hybridization:  
Identical RNA samples were used for the comparison of the different microarray 
experiments. Labeling and subsequent hybridization of microarrays were performed 
consistently in the laboratories of BfArM and Miltenyi Biotec.  
In both laboratories the quality of RNA was examined by the RIN-values (Agilent 2100 
Bioanalyzer). The concentration and purity of extracted RNA was measured using an UV-
visible spectrometer (NanoDrop 1000; Thermo Fisher Scientific, Waltham, MA) by absorption 
at wavelengths of 260 and 280 nm. RNA samples with a 260/280 nm absorption ratio > 1.8 
and RIN > 9.5 were used in a subsequent microarray analysis. Microarray experiments were 
performed with 100 ng of total RNA and cRNA was generated using reverse transcriptase. In 
both laboratories one-colour labeling was performed with Cy3-dCTP during the amplification 
reaction. The Cy3 dye incorporation efficiency was evaluated using a NanoDrop 1000 
spectrophotometer and showed efficiencies of ≥17 fmol/ng.  
After fragmentation (60 °C, 30 min in BfArM and 65 °C, 30 min at Miltenyi Biotec), the single 
colour cRNA samples were hybridized to a DNA chip (Whole Genome Gene Expression 
Microarrays v2, Agilent Technologies, 8x60K in BfArM and Whole Genome Gene Expression 
Microarrays, Agilent Technologies, 8x60K at Miltenyi Biotec) at 65 °C for 17 hours in a 
hybridization oven (Agilent Technologies). Four independent experiments were performed 
under each experimental condition.  
Different microarray platforms were used for the microarray experiments (tab. 10) and the 
samples were labeled by the same method. The biological features investigated by the 
different microarray platforms differed. SurePrint G3 Human Gene Expression 8x60K v2 
Microarray Kit a recently developed microarray from Agilent Technologies showed an update 
of mRNA and long intergenic non-coding RNA (lincRNA) probes from the Broad Institute 
(www.genomics.agilent.com/article.jsp?crumbAction=push&pageId=1516/; 9.2.2014).  
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Tab. 10: Details and specifications of microarrays used for interlaboratory comparison in our 
laboratory and at Miltenyi Biotec. 
 Miltenyi Own laboratory 
Labeling SurePrint G3 Human Gene  
Expression 8x60K Microarray Kit 
SurePrint G3 Human Gene 
Expression 8x60K v2 Microarray 
Kit 
Format 8 x 60 K 8 x 60 K 
Manufacturing Agilent 60-mer SurePrint 
technology 
Agilent 60-mer SurePrint 
technology 
Biological features Target 27,958 Entrez Gene RNAs 
7,419 lincRNAs 
50,599 
Positive controls 96 x 10 ERCC control probes 
10 x 32 E1A spike-in control 
probes 
96 x 10 ERCC control probes 
10 x 32 E1A spike-in control 
probes 
Composition Design based on: 
• RefSeq Build 36.3 
• Ensemble Release 52 
• Unigene Build 216 
• GenBank (April 2009) 
• Plus: novel content for 
lincRNAs (long intergenic 
noncoding RNAs) 
Design based on: 
• RefSeq Build 50 
• Ensemble Release 52 
• Unigene Build 216 
• GenBank (April 2009) 
• Broad Institute Human 
lincRNA catalog (Nov 2011) 
• Broad Institute TUCP 
transcripts catalog (Nov 
2011) 
Microarray data analysis:  
Hybridized DNA chip slides were scanned using an Agilent Scanner (Agilent Technologies) 
with Feature Extraction Software (Agilent Technologies). Fluorescence intensity data from 
both laboratories were imported into GeneSpring GX version 12.5 (Agilent Technologies) and 
normalized using quantile scaling. In a first step serving quality control, data were filtered to 
exclude low-quality data. Biological features with lower intensities than the threshold and 
biological features with saturated intensities were excluded. Finally, biological features with 
at least twofold regulation were used for the statistical data analysis. The statistical analysis 
was performed with a t-test corrected using the Benjamini and Hochberg false discovery rate 
(Benjamini Y., 1995). Genes were considered as significantly altered with an at least twofold 
regulation and p < 0.05. 
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6.4 Results 
RNA quality and labeling results: 
RIN values in both laboratories indicated RNA of good quality (RIN ≥ 9.5). Cy-3 dye 
incorporation efficiency was higher in our laboratory than at Miltenyi Biotech. According to 
the recommendations from Agilent Technologies, both Cy-3 incorporation rates were 
adequate for microarray hybridization.  
Interplatform correlations: 
A common gene annotation (Entrez Gene ID) was used to match the gene identities 
represented for both microarrays for the comparison of the different platforms. In total, 
30,746 biological features were common for both microarray platforms (fig. 24).  
 
Fig. 24: The number of Entrez Gene identifiers 
represented by both Agilent microarray platforms. The 
Venn diagram shows that 30,746 biological features are 
represented by both platforms.  
The statistical data evaluation revealed a different number of differently regulated biological 
features after exposure to the different Chelidonii herba extracts, respectively (fig. 25). As 
expected, a large proportion of the biological features was unaltered after exposure of 
HepG2 to the different Chelidonii herba extracts for both types of microarray platforms.  
Most regulated biological features for both array platforms were observed for gene 
expression profiles of the ethanolic extract (fig. 25). Microarray experiments with the 
dichloromethane extract indicated 150 significantly regulated genes for both array platforms. 
The gene expression profiles obtained after exposure to the ethanolic 50% (V/V) extract 
revealed 108 commonly regulated genes while less commonly regulated genes were shown 
for the aqueous extract of Chelidonii herba.  
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Fig. 25: Overlap of significantly (p< 0.01, fold change ≥ 2 and ≤ -2) affected genes by the 
different Chelidonii herba extracts, identified by the different Agilent platforms. Experiments 
with the dichloromethane (A), ethanol (B), ethanol 50% (V/V) and aqueous (D) Chelidonii herba 
extracts were compared. 
Several genes represented for both microarray platforms were shown to be significantly 
regulated just by one microarray platform. A more detailed analysis of regulated genes just 
by one microarray platform revealed that most of them were regulated less than threefold 
(tab. 11). 
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Tab. 11: Percentage of regulated genes (fold change ≤ 3 and ≥ -3, p ≤ 0.01) represented for both 
microarray platforms. 
Technical reproducibility:  
In the present study the experimental reproducibility was accessed by those genes that were 
represented for both microarray platforms. Several genes were regulated in common on both 
microarray platforms (tab. 12). The analysis of the gene expression data demonstrated a few 
genes that were differently regulated on the two microarray platforms. For exposure of 
HepG2 cells to the dichloromethane extract 15 genes (10.0%) were identified that were 
controversially regulated while for exposure to the ethanolic extract 17 (8.1%) of the 
commonly regulated genes were differentially regulated. Exposure to the ethanolic 50% (V/V) 
and the aqueous extract demonstrated four (3.7%) and eight (22.9%) controversially 
regulated genes, respectively. The correlation of differentially regulated genes with an at 
least threefold regulation indicated higher correlation results. After exposure to the 
dichloromethane extract, eight genes (5.3%) and for the ethanolic extract five genes (2.4%) 
were differentially regulated. After exposure to the ethanolic 50% (V/V) and the aqueous 
extracts two genes (1.9% and 5.7%, respectively) were differently regulated.  
  
Experimental condition BfArM (%) Miltenyi (%) 
Dichloromethane extract 70.3 64.4 
Ethanolic extract 86.0 68.7 
Ethanolic 50% (V/V) extract 84.4 69.0 
Aqueous extract 83.0 60.0 
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Tab. 12: Correlation between the expression data of technical replicates analyzed by different 
microarray platforms. 
Experimental condition 
Commonly regulated 
genes 
Differently regulated 
genes 
Dichloromethane extract 135 15 
Ethanolic extract 194 17 
Ethanolic 50% (V/V) extract 104 4 
Aqueous extract 27 8 
Affected biological pathways: 
To identify affected biological pathways across both microarray platforms Genespring 12.5 
software (Agilent Technologies) was used. The analysis of significantly affected pathways 
and signal cascades was performed with significantly regulated genes common to both 
microarray platforms. 
The highest number of regulated pathways was obtained for exposure to the ethanolic 
Chelidonii herba extract (fig. 26), 25 signal cascades being commonly regulated. After 
exposure to the aqueous Chelidonii herba extracts 13 commonly regulated biological 
pathways were observed. The exposure of the dichloromethane and the ethanolic 50% (V/V) 
extracts induced ten and eleven biological pathways in common, respectively.  
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Fig. 26: Venn diagrams showing the overlap of biological processes significantly affected 
(p<0.005) by the different Chelidonii herba extracts, identified by the different Agilent 
platforms. Comparisons were made for experiments with the dichloromethane (A), ethanol (B), 
ethanol 50% (V/V) and aqueous (D) Chelidonii herba extracts.  
6.5 Discussion 
Because of increasing application of microarray technology to analyze the whole 
transcriptome there is necessary to assess the comparability of microarray data obtained in 
different laboratories or by different platforms. In the present study, identical RNA samples 
were investigated to analyze the reproducibility and biological significance. Hence, biological 
variation can nearly be excluded to be responsible for variation. Only the period of storage 
has to be considered as a parameter for the biological variation. In previous studies, it was 
shown that prolonged storage may influence results obtained by microarray results (Hatzis 
C., 2011).  
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The correlation of genes obtained in the present study, represented for both microarray 
platforms, indicated that at least 77% of genes showed the same direction of fold change. A 
more detailed analysis revealed that mostly genes with lower expression levels (threefold 
regulation) were responsible for the variability. Previous studies already indicated higher 
variance for small fold changes (Baum M., 2003; Dobbin K., 2005).  
In the literature there are controversial reports on the assessment of reproducibility of 
interplatform and interlaboratory experiments. A previous study that compared interplatform 
and interlaboratory differences showed that laboratory effects had a larger impact on the 
precision of microarray data than interplatform effects (Irizarry R., 2005). In contrast, the 
MicroArray Quality Control (MAQC) project showed a good concordance of interplatform data 
(Guo L., 2006). Recently, gene expression profiles investigated with microarray techniques 
and RNA sequencing methods, different in terms of technology, showed good concordance 
(Arino J., 2013; Guo Y., 2013), thus indicating the advancements in microarray technology. 
In conclusion, it was shown that variability in the gene expression profiles depend on 
different laboratories, experimenters and microarray platforms. Fold changes in mRNA 
expression were relatively low. However, genes altered threefold indicated higher 
congruency. The comparison of data may lead to the suggestion that genes with higher fold 
changes should be received for systems biological data evaluation. However, current 
microarray studies frequently use statistically significant and twofold regulated genes for 
further analysis.  
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7 Authentication of different Artemisia sp. by complementary 
methods 
7.1 Abstract 
Background: For quality control and safety of medicinal plants it is indispensable to identify 
and authenticate herbal substances. In this study, multidisciplinary methods were 
investigated for their applicability in complementary quality assessment of herbal substances. 
As a model, different Artemisia sp. (Artemisiae annuae herba, Artemisiae scopariae herba, 
Artemisiae argyi folium) were analyzed, which are also used in traditional Chinese medicine 
(TCM). Furthermore, A. scoparia Waldst. & Kit. samples from different provenances were 
examined. 1H-NMR analysis together with principal component analysis was applied and 
PCR-based methods were used to identify herbal substances.  
Using the metabolomics-based approach, different Artemisia sp. and Artemisia scoparia 
samples from different provenances were extracted using dichloromethane in triplicates. 1H-
NMR fingerprints were recorded and evaluated by PCA. Using a PCR-based approach, the 
internal transcribed spacer region (ITS) was analyzed. Additionally, for A. scoparia the 
external transcribed spacer region (ETS) was used and investigated using NCBI BLAST 
database. 
Results: Clustering results were obtained for the different Artemisia sp. by 1H-NMR 
fingerprint and PCA. Using the PCR-based approach with ITS primers, according to NCBI 
BLAST, A. annua and A. argyi were identified. Furthermore, by PCA A. scoparia samples 
from different geographical origins were discriminated. By the analyses of both, ITS and ETS 
sequence data, Artemisia scoparia samples were unambiguously identified.  
Conclusion: Investigations of Artemisia sp. have illustrated that 1H-NMR analysis in 
combination with PCA are useful in the characterization of herbal substances and their 
preparations. Identification of herbal substances by analysis of DNA marker regions presents 
a considerable potential for identification of herbal substances complementary to 
macroscopic, microscopic and chromatographic fingerprinting methods. To unambiguously 
identify herbal substances at least two marker regions should be used.  
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7.2 Introduction 
In Europe there is an increasing trade with herbal substances and products derived thereof 
traditionally used in China and India (Patwardhan B., 2005). The study of macroscopic and 
microscopic characters of the herbal substances is not always sufficient and the distinction of 
taxonomically closely related herbal substances can be challenging. Recent progress based 
on metabolomic and molecular approaches offers a set of powerful methods investigated in 
the present study.  
Beside mass-spectrometric methods, 1H-NMR spectroscopy is an approach to characterize 
the metabolome. By 1H-NMR spectroscopy it is possible to detect all proton-bearing 
compounds within one sample. For plant extracts most “organic” compounds are covered: 
carbohydrates, amino acids, fatty acids, amines, ethers, esters and lipids (Ward J., 2003). 
Other approaches used to identify herbal substances are molecular methods. In terms of 
quality control, molecular methods may complete analytical testing, but usually they do not 
replace methods like TLC or HPLC. Most of the molecular approaches are PCR-based and 
often include sequencing of DNA of marker regions.  
The genus Artemisia comprises about 350 to 500 species (Riggins C., 2012). In the Chinese 
Pharmacopoeia 2010, four Artemisia sp. are monographed: Artemisiae argyi folium 
(Artemisia argyi Levl. et Vant. [Aiye]), Artemisiae scopariae herba (A. scoparia Waldst. & Kit. 
and Artemisia capillaris Thunb. [Yinchen]) and Artemisiae annuae herba (Artemisia annua L. 
[Qinghao]).  
Recent phytochemical research on A. scoparia resulted in the detection of different 
secondary metabolites, including essential oil constituents like the monoterpene 
hydrocarbons α-myrcene, p-cumene, geranyl acetate and acetylisoeugenol, furthermore 
sequiterpenes, such as caryophyllene oxide and aromatic compounds (phenylmethanal and 
capillin) (Cha J., 2005; Sharopov F., 2011; Singh H., 2010). Additionally, flavones and 
flavonoids like eupatolitin glycosides, quercetin, scoparon, and scopoletin have been isolated 
(Chandrasekharan I., 1981).  
A. annua is an herb from which the sesquiterpene lactone artemisinin was isolated, which is 
an antiplasmodial compound (White N., 1997). Further constituents identified in Artemisiae 
annuae herba are artemisia ketone, α-pinene, and 1,8-cineole (Radulovic N., 2013). 
Furthermore, some flavone compounds like artemetin (Elford B., 1987; Weathers P., 2012), 
scopoletin (Melillo de M., 2012), and scopoline (van der Kooy F., 2013) were identified for 
this herbal substance.  
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A. argyi contains flavones like quercetin (Tan R., 1992), scopoletin and isoscopoletin (Adams 
M., 2006), a number of essential oils like borneol (Li N., 2008), sesquiterpene ketones 
(Yoshikawa M., 1996) and the monoterpenes α-myrcene, α-pinene, and limonene (Li N., 
2008).  
The aim of this study was to evaluate the potential of complementary methods to identify and 
authenticate herbal substances. As a model, different Artemisia sp. that are monographed in 
the Chinese Pharmacopoeia 2010 (Artemisiae argyi folium, Artemisiae scopariae herba and 
Artemisiae annuae herba) were analyzed. In addition, A. scoparia samples from different 
provenances were investigated (fig. 27). Regarding the cultivation area, the phenotype from 
the different samples widely differed. 
A 
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Fig. 27: Artemisia scoparia from Chinese import (A) and cultivated in Germany (B), adopted 
from (Scherübl R., 2012). 
With an analytical approach, a metabolomic fingerprint of different Artemisia sp. with 1H-NMR 
analysis combined with PCA was investigated. The potential to identify herbal substances by 
marker sequences was investigated by analysis of the ITS. Moreover, A. scoparia samples 
from different geographical origins were additionally investigated by the analysis of ETS.  
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7.3 Materials and Methods 
Herbal substance material:  
Artemisia sp.:  
For the investigation of the metabolome and ITS Artemisiae scopariae herba, Artemisiae 
argyi folium and Artemisiae annuae herba were obtained from different pharmacies and 
suppliers (tab. 13).  
Tab. 13: Herbal substances and herbal medicinal product and sources used in this study sing 
PCR-based approach and metabolomics based method. 
 
Herbal substance Source 
Artemisiae annuae herba Caesar & Loretz GmbH (Hilden, Germany) 
Complemedis AG (Schönenwerd, Switzerland) 
(Granulate) 
Kaiser pharmacy (Bonn, Germany) 
Artemisiae argyi folium Complemedis AG (Schönenwerd, Switzerland) 
Kaiser pharmacy (Bonn, Germany) 
Artemisiae scopariae herba Complemedis AG (Schönenwerd, Switzerland) 
Galke (Bad Grund, Germany) 
Kaiser pharmacy (Bonn, Germany) 
Additionally, further herbal substances were investigated using 1H-NMR analysis in 
combination with PCA (tab. 14). The herbal substance Artemisiae annuae herba from 
Complemedis AG (tab. 13) was excluded as it was a granulated herbal medicinal product. 
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Tab. 14 Herbal substances used in this study using the metabolomics-based method. 
 
Herbal substance Source 
Artemisiae annuae herba Herba Sinica Hilsdorf GmbH (Rednitzhembach, Germany) 
PharmaChin GmbH (Berlin, Germany) 
Pharmacy (Singapore) 
SinoPhytoMed GmbH (Waldsassen, Germany) 
Artemisiae argyi folium Caesar & Loretz GmbH (Hilden, Germany) 
Artemisiae scopariae herba Herba Sinica Hilsdorf GmbH (Rednitzhembach, Germany) 
SinoPhytoMed GmbH (Waldsassen, Germany) 
Artemisia scoparia from different provenances: 
In total, 18 A. scoparia samples from different provenances were investigated in this thesis 
(tab. 15). Eight of the plants were cultivated in Germany (Steinach [Straubing] and 
Forstwiesen [Ingolstadt]). Plant material was harvested in spring at a height of 60-80 cm, with 
the exception of one flowering sample collected in autumn. The plant was identified by DNA 
sequencing (Heuberger H., 2010). 
In China, ten herbal samples were cultivated investigated in this thesis. The aerial parts of A. 
scoparia from China were purchased from the suppliers Arobemed, Lian, Pharmachin, 
Phytax and one sample was provided by the Heilongjiang University of Chinese Medicine, 
Harbin China. Three more samples were obtained from the manufacturer Yong Quan and 
imported from Chengdu and Shanghai.  
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Tab. 15 Artemisiae scopariae herba from China and from Germany investigated in the present 
study.  
 
Provenance Source 
Germany Lfd 14 
 Lfd 15  
 Lfd 16 
 Lfd 17 
 Lfd 18 
 Lfd 19 
 Lfd 20 
 Lfd 21 
China Arobemed (Emmendingen, Germany) 
 Hangzhou (local pharmacy) 
 Herba Sinica Hilsdorf GmbH (Rednitzhembach, Germany) 
 Lian (Wollerau, Switzerland) 
 PharmaChin GmbH (Berlin, Germany) 
 Phytax (Schlieren, Switzerland) 
 Yong Quan (Shanghai 2001) (Ennepetal, Germany) 
 Yong Quan (Shanghai 2005) (Ennepetal, Germany) 
 Yong Quan (Chengdu 2009) (Ennepetal, Germany) 
 University of Chinese medicine (Harbin, China) 
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Extraction of Artemisia herbal substances: 
The herbal substance was powdered by a mill and 300 mg were extracted with 10 ml 
dichloromethane for 15 min. After filtering, the solvent was eliminated under reduced 
pressure and the dried extract was resolved in 500 µl deuterated acetone. Three replicates of 
each of the herbal preparations were prepared and analyzed by 1H-NMR in the same 
manner.  
1H-NMR analysis and PCA: 
1H-NMR spectra of extracts were recorded with a Bruker advance 300 DPX instrument 
(temperature 25 °C, 64 scans). Calibration of spectra was performed according to signals of 
incomplete deuterated solvents. Data were processed using TOPSPIN software and 
evaluation by PCA was performed with AMIX software (Bruker). Spectral data from δ 10 to 
δ 0 ppm were included for PCA. The region from δ 7.1 to δ 7.4 ppm was excluded for PCA 
because of signals from residual acetone in the extract. The bucket width was 0.05 ppm and 
data were integrated according to the sum of intensities.  
Extraction of DNA: 
DNA extraction was performed using a PSP Spin Stool DNA Kit (Stratec, Berlin, Germany) 
according to the manufacturer’s protocol. 50 mg of the powdered herbal substance was used 
for DNA extraction. 
PCR: 
ITS was amplified using previously established universal plant specific ITS primers (TKA-for: 
5’-GAACCTGCGGAAGGATCATTG-3’, TKA-rev: 5’-GCTTAAACTCAGCGGGTAGTCC-3’) or 
(TKB-for: 5’-GCAGGTTCACCTACGGAAAC-3’; TKB-rev: 5’- CGCGACCCCAGGTCA-3’) 
(ITS1: 5’-TCCGTAGGTGAACCTGCGG-3; ITS4: 5’-TCCTCCGCTTATTGATATGC -3) 
(Kersten T., 2013). Primers applied to amplify ETS were specific for A. scoparia (ETS 
Artemisia for: 5´-GTGCGGCAAGGCTTGTATCG-3´; ETS Artemisia rev: 5´-
ACCGCGTCAAGGTTCACCTC-3´). PCR was performed in a total volume of 25 µl consisting 
of 1×PCR buffer, 0.5 µl template DNA, 0.1 µM of each primer (Eurofins MWG Operon, 
Germany) and 0.25 µl DNA polymerase (Promega, Germany). PCR included an initial 
denaturation step at 95 °C for 2 min, followed by 35 cycles for 30 s at 94 °C, 20 s at 60 °C 
and 30 s with 72 °C; and a final extension period of 4 min at 72 °C. PCR products were 
analyzed by agarose gel electrophoresis.  
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PCR sample clean up and sequencing reaction: 
Purification of PCR fragments was performed by using a QIAquick Gel Extraction Kit or 
QIAquick PCR Purification Kit according to the manufacturer´s instructions (Qiagen GmbH).  
Sequencing results were obtained by GATC Biotech AG (Konstanz, Germany). To improve 
the quality of sequencing data, amplicons were ligated using pGEM-T vector system 
(Promega, Mannheim, Germany) and transformed with competent E. coli XL1 blue. The 
transformants were plated on LB-ampicillin plates and selected colonies were cultivated in 
LB medium containing ampicillin (100 µg/ml) overnight (37 °C). Plasmid DNA was isolated  
using PureYield Plasmid Miniprep System (Promega, Germany) according to the 
manufacturer’s protocol.  
Sequence-data analysis: 
By NCBI BLAST alignments (National Center for Biotechnology, www.ncbi.nlm.nih.gov/) a 
sequence similarity search was performed to identify sequences with similarity. 
7.4 Results 
1H-NMR analysis: 
NMR-fingerprint analysis of different Artemisia sp.:  
In a previous research project, the 1H-NMR spectra of some Artemisia sp. were already 
analyzed (Daniel C., 2009). In the present study, the data were evaluated by PCA to 
evaluate the 1H-NMR-based approach more in detail. In total, three different Artemisia sp. 
were analyzed: Artemisiae argyi folium, Artemisiae annuae herba and Artemisiae scopariae 
herba. 
PCA demonstrated differences between the three different Artemisia samples (fig. 28). 
Samples of Artemisiae annuae herba, Artemisiae argyi folium and Artemisiae scopariae 
herba were classified, respectively. The distribution of the clusters indicated that Artemisiae 
argyi folium and Artemisiae scopariae herba represented the highest variability.  
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Fig. 28: Score plot of PCA of PCs of 
1
H-NMR spectra of 
dichloromethane extracts of Artemisiae annuae herba 
(black), Artemisiae argyi folium (blue) and Artemisiae 
scopariae herba (green). The extracts were analyzed in 
acetone-d6. 
Examination of the loading plot (fig. 29) showed that the first and second principle 
component (PC) explained the variance associated with aliphatic constituents since high 
loading values were observed in this region of the 1H-NMR-spectra. The main differences 
between the extracts were found in the region from about δ 3.5 to δ 0.5 ppm, where most of 
the protons associated with terpenoids, steroids, and organic acids resonate. In addition, the 
loading plot of PC1 and PC2 illustrated a few positive and negative regions of the spectra at 
about δ 4.0 ppm. In this region, most of the protons of carbohydrates, amino acids, and 
glycosides resonate. Signals between δ 6.0 and δ 5.5 ppm indicate that molecules 
associated with flavonoids, phenylpropanoids, phenolics, and tannins were less determining 
for the variance of the different extracts compared to signals observed in the upfield region. 
 
 
Fig. 29: 1D loadings for PC1 (black) and PC2 (blue) of different Artemisia sp. 
(Artemisiae annuae herba, Artemisiae argyi folium and Artemisiae scopariae 
herba). Scaling corresponds to the chemical shift (ppm) of 
1
H-NMR spectra. 
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NMR-fingerprint analysis of A. scoparia from Germany and China 
In this part of the study, extracts were prepared from samples of A. scoparia. 1H-NMR 
spectra were analyzed in analogy to the approach used for the investigation of different 
Artemisia sp.. The score plot of PCA (fig. 30) showed discriminable cluster formation of the 
A. scoparia samples from China and Germany, respectively.  
 
 
Fig. 30: Score plot of PCA of the first three PCs of 
1
H-NMR 
spectra of dichloromethane extracts of A. scoparia from 
China (blue) and Germany (black). The extracts were 
analyzed in acetone-d6. 
The loading plot of PC1 and PC2 (fig. 31) illustrated that most positive and negative regions 
of the spectra were located between δ 3.5 and δ 0 ppm, a region associated with protons 
from terpenoids, steroids and organic acids. Signals in the spectra between δ 5.0 and 
δ 6.0 ppm associated with protons from flavonoids, phenylpropanoids and phenolics 
indicated a minor impact of variance compared to the upfield region.  
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Fig. 31: 1D loadings for PC1 (black) and PC2 (blue) of A. scoparia from China 
and Germany. Scaling corresponds to the chemical shift (ppm) of 
1
H-NMR 
spectra. 
Analyses of ITS and ETS: 
ITS sequences obtained for the different Artemisia sp. were investigated. Some data were 
already received in a previous research project in our group (Daniel C., 2009). In the present 
study, they were re-evaluated by NCBI BLAST analysis (tab. 16).  
Three different Artemisiae annuae herba samples were investigated. Sequencing results 
were obtained for 5´→3´direction and for 3´→5´direction using the ITS1, ITS4, TKB forward, 
and TKB reverse primer, respectively. According to NCBI BLAST, the herbal substances 
were identified as Artemisia annua, respectively.  
Additionally, two Artemisiae argyi folium samples were investigated and sequence identity 
showed 100%; thereby, the NCBI BLAST hit result confirmed the identity of A. argyi L..  
According to NCBI BLAST, the analyzed Artemisiae scopariae herba samples corresponded 
to Artemisia sp.. However, one exception was observed, as one sample indicated higher 
similarity to Artemisia japonica. The investigated ITS sequences obtained for A scoparia 
were highly similar.  
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Tab. 16: Different Artemisia sp. investigated in the present study. 
 
NCBI accession 
code 
Identified 
species (NCBI 
BLAST) 
PCR and 
sequencing 
deoxynucleotides 
Artemisia annua 
   
Artemisiae annuae herba, 
Complemedis 
AY548199.1 Artemisia annua ITS1 
Artemisiae annuae herba, 
Complemedis  
GU724282.1 Artemisia annua ITS4 
Artemisiae annuae herba, 
Kaiser pharmacy 
AY548199.1 Artemisia annua ITS1 
Artemisiae annuae herba, 
Kaiser pharmacy 
GU724282.1 Artemisia annua ITS4 
Artemisiae annuae herba, 
Caesar & Loretz  
JQ230972.1 Artemisia annua TKB for 
Artemisiae annuae herba, 
Caesar & Loretz  
JQ230972.1 Artemisia annua TKB rev 
Artemisia argyi 
   
Artemisiae argyi folium, 
Complemedis  
GU724270.1 Artemisia argyi TKB for 
Artemisiae argyi folium, 
Kaiser pharmacy 
GU724270.1 Artemisia argyi TKB for 
Artemisia scoparia 
   
Artemisiae scopariae 
herba, Kaiser pharmacy 
GU724303.1 
Artemisia 
scoparia 
ITS1 
Artemisiae scopariae 
herba, Complemedis 
AY548200.1 
Artemisia 
japonica 
ITS1 
Artemisiae scopariae 
herba, Galke  
GU724303.1 
Artemisia 
scoparia 
TKA forw 
Artemisiae scopariae 
herba, Galke 
GU724303.1 
Artemisia 
scoparia 
TKA rev 
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Additionally, ITS sequences from A. scoparia samples from different provenances were 
investigated using TKA deoxynucleotides and specific ETS deoxynucleotides for 
identification of herbal samples. The alignment of the different sequences showed no major 
differences in the analyzed ITS and ETS sequences, respectively. According to the NCBI 
BLAST alignment of the obtained ITS sequences, one sample showed more similarity to 
Artemisia japonica. For the remaining A. scoparia samples, the highest accordance was 
shown for Artemisia sp..  
ETS sequences were additionally investigated to assure the identity of the A. scoparia 
samples. According to NCBI BLAST alignment, all samples showed the highest similarity to 
A. scoparia (tab. 17).  
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Tab. 17: Sequencing results of ITS and ETS of A. scoparia samples from China and Germany. 
 ITS  ETS 
 
NCBI 
BLAST 
result 
NCBI 
accession 
code 
 NCBI 
BLAST 
result 
NCBI 
accession 
code 
Germany      
Lfd 14 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 15  A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 16 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 17 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 18 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 19 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 20 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lfd 21 A. scoparia FJ528303.1  A. scoparia DQ028857.1 
China      
University of 
Chinese medicine 
A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Herba Sinica A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Lian A. scoparia FJ528303.1  A. scoparia DQ028857.1 
PharmaChin A. japonica GU724289.1  A. scoparia DQ028857.1 
Yong Quan 
(Shanghai 2001) 
A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Yong Quan 
(Shanghai 2005) 
A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Phytax A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Yong Quan 
(Chengdu 2009) 
A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Arobemed A. scoparia FJ528303.1  A. scoparia DQ028857.1 
Hangzhou 
(pharmacy) 
A. scoparia FJ528303.1  A. scoparia DQ028857.1 
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7.5 Discussion 
The appropriate quality and safety of herbal medicinal products is obligate for licensing. 
Fundamental steps for a safe use have to include the identification and authentication of the 
plant species. Therefore, complementary methods are of special interest for the analyses of 
herbal substances and preparations thereof, also from non-European origin. Artemisia sp. 
have been used in health care for centuries in various Asian countries (Kalemba D., 2002; 
Kordali S., 2005). Thus, it is an interesting model object to test the applicability of 
complementary methods for quality control of medicinal plants.  
In the present study, Artemisia sp. monographed in the Chinese Pharmacopoeia 2010, were 
investigated by 1H-NMR fingerprinting. PCA differenciated Artemisiae argyi folium, 
Artemisiae scopariae herba and Artemisiae annuae herba into different groups indicating that 
this method can adequately discriminate different herbal substances. Secondary metabolites, 
mainly responsible for differences in sample composition were mainly associated with 
terpenoids, steroids and organic acids. In previous studies, terpenoids were identified as 
phytochemical constituents of Artemisia sp. (Harada R., 1982; Ahmad A., 1994; Singh H., 
2009; Cavar S., 2012).  
Artemisinin is a sesquiterpene endoperoxide lactone identified for A. annua frequently used 
in the treatment of malaria. The structure of artemisinin using 1H-NMR and 13C-NMR 
assignments previously was investigated (Blaskó G., 1988; Wallaart T., 1999). In the present 
study, for preparations containing Artemisiae annuae herba, small signals were obtained at 
δ 5.86 ppm and δ 1.44 ppm in the 1H-NMR spectra that may be associated with artemisinin. 
However, multitudes of partly overlapping signals were observed in the 1H-NMR spectra in 
the region from δ 2.5 to δ 0.5 ppm. Therefore, it is difficult to identify molecules exactly 
responsible for the classification of preparations containing Artemisia.  
Furthermore, the metabolomics-based approach was used to characterize morphologically 
different Artemisia scoparia samples from different provenances. It was previously shown 
that environmental factors may have an important influence on the metabolome (Brunetti C., 
2013). For A. annua it was already shown that its antimalarial compound artemisinin varies 
depending on the time of harvest (Wallaart T., 2000). Moreover, in previous studies, it was 
shown that the provenance strongly influences the secondary metabolite profile (Sellami H., 
2013). The loading plot indicated that secondary metabolites responsible for the classification 
of samples were mainly associated with steroids, terpenoids, organic acids, and to minor 
amounts with flavonoids, phenoloics and tannins. In a previous study, identical A. scoparia 
samples from Germany and China were investigated (Scherübl R., 2014). It was shown by 
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standard methods that the flavonoid quercitrin was exclusively present in the German 
samples. The essential oils capillene (10.1-46.0%), spathulenol (3.5-17.0%), and 
hexadecanoic acid (1.0-37.6%) were identified as the major constituents represented in A. 
scoparia from both provenances. Furthermore, in the study performed by R. Scherübl et al., it 
was shown that fatty acids were present in higher amounts in A. scoparia from China than 
from Germany. The samples from Germany revealed higher amounts of monoterpenes. 
Further differences were identified among the sesquiterpenes. Bisabolane-type derivatives 
were identified predominately within the samples originating from Germany, whereas 
cadinane-type ones accumulated mostly in the Chinese samples (Scherübl R., 2014). 
Interestingly, in the present study, the loading plot indicated variance between the extracts 
from different provenances associated with terpenoids, steroids and organic acids, 
flavonoids, phenylpropanoids and phenolics. Hence, for classification the same groups of 
phytochemical constituents were identified. 
Before herbal preparations are marketed in Europe, the identity has to be determined as 
specified in the European Pharmacopeia or in a national pharmacopoeia. For this purpose, 
macroscopic, microscopic, and fingerprinting techniques are frequently used. Additionally, 
the content of specific marker compounds is often determined. However, chromatographic 
techniques and the use of marker compounds showed limitations. Some rare and expensive 
medicinal plants were adulterated with morphological related species or spiked with marker 
substances (Joshi K, 2004). Hence, a DNA-based approach may be useful to overcome 
these problems. The marker sequence ITS2 was determined as a useful DNA marker to 
identify species of the Asteraceae family (Gao T., 2010). This may lead to the suggestion 
that the usage of ITS might be an appropriate a marker region for the identification of 
Artemisia sp.  
The results of the present study showed that the analysis of ITS sequences was useful for 
the identification of different Artemisia sp.. However, it was shown that minor changes in the 
sequence may lead to differing NCBI BLAST results. According to NCBI BLAST alignment, 
one A. scoparia sample showed more similarity to the related species A. japonica. By the 
usage of a second marker sequence, the herbal substance was confirmed to be Artemisia 
scoparia. Hence, it is very useful to consult at least two marker sequences for unambiguous 
identification, as it is also proposed by various previous studies (CBOL Plant Working Group, 
2009; Kuzmina M., 2012; Mankga L., 2013; Zhang W., 2013).  
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In conclusion, the metabolomics-based approach enabled comprehensive assessment of 
complex herbal substances. The applicability of this approach has already been positively 
evaluated in previous studies (Chauthe S., 2012; Daniel C., 2008; Frederich M., 2011; Kim 
H., 2005; Mattoli L., 2006; Politi M., 2009; van der Kooy F., 2009). In the present study, 
different Artemisia sp. with a traditional use in Asia were authenticated by 1H-NMR analysis 
combined with PCA. Additionally, differences in the metabolome of the medicinal plant A. 
scoparia from two provenances were displayed by this approach. Interestingly, differences in 
the composition of herbal constituents confirmed previously published results that were 
obtained by standard methods (TLC, HPLC/MS, GC/MS) (Scherübl R., 2014). The identity of 
different Artemisia samples was revealed by the PCR-based approach and the application of 
two marker sequences. Especially for herbal substances belonging to TCM this is a very 
meaningful approach. However, herbal substances from non-European origin are often 
processed. Subsequently, DNA may be degraded and PCR-based techniques are not 
suitable (Kersten T., 2008).  
Thus, the comprehensive application of both approaches is a useful strategy to identify and 
authenticate herbal substances and preparations thereof. Overall, the present study clearly 
proposes 1H-NMR fingerprinting along with the statistical method PCA to authenticate herbal 
substances in combination with PCR-based methods for the identification of herbal 
substances.  
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8 Overall discussion 
8.1 Bridging: chemical profile and functional activity 
The quality of herbal substances and their preparations is of paramount importance for their 
safety and efficacy. Therefore, this study investigated the potential of recently developed 
methodologies, such as metabolomic profiling and gene expression profiling, to complement 
standard methods for characterization of herbal substances and their preparations.  
Herbal substances and their preparations are complex in nature due to their high number of 
constituents; hence, the appropriate chemical characterization is indispensable. Therefore, a 
strategy was chosen that included the chemical characterization based on a metabolomics-
based approach (Daniel C., 2009). In addition, herbal preparations were analyzed by 
pharmacopeial monographs. The biological functions were investigated by the 
characterization of cellular responses using gene expression profiling and analysis of cell 
proliferation.  
Three different herbal substances were investigated. Two of them, Chelidonii herba and 
Cimicifugae racemosae rhizoma, are associated with liver toxicity. The third investigated 
herbal substance, Silybi mariani fructus, has traditionally been used to treat toxic liver 
damage and also for the supportive treatment of chronic inflammatory liver diseases. The 
project was designed to investigate a broad spectrum of herbal preparations, but not to focus 
on herbal medicinal products available on the market. Some extracts were prepared similar 
to commercially available herbal preparations, because respective extraction solvents used 
are known to be potent in extracting the active substance/s. However, other extraction 
solvents were used to obtain extracts with different composition. This strategy was shown to 
be very useful in the complementary investigation of herbal substances.  
The alkaloids sanguinarine and chelerythrine represented in Chelidonii herba were 
suggested to be liver-toxic (Dvorak Z., 2006b; Kosina P., 2004; Ulrichová J., 1996). Four 
different herbal extracts with different patterns of constituents were investigated. In finished 
herbal medicinal products containing Chelidonii herba, a mixture of ethanol and water is a 
frequently used extraction solvent. Accordingly, ethanol and ethanol 50% (V/V) were 
included in the present study. In addition, water and dichloromethane were used as these 
solvents are of different polarity.  
The correlation of the chemical profile and cell proliferation suggested that antiproliferative 
effects were not exclusively associated with the alkaloid content. Gene expression data and 
systems biological data evaluation revealed that the different constituents in the respective 
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extracts activated different signal cascades. Major differences were demonstrated in signal 
cascades related to biotransformation and liver toxicity. 
Preparations derived from Cimicifugae racemosae rhizoma are widely used in the population; 
however, cases of liver toxicity have been reported. Three different preparations containing 
Cimicifugae racemosae rhizoma were investigated and were analyzed in analogy to 
preparations derived from Chelidonii herba. Isopropanol and mixtures of ethanol and water 
are frequently used solvents used in commercially available preparations containing 
Cimicifugae racemosae rhizoma. Hence, in the present study, ethanol and 50% ethanol were 
used as extraction solvents and additionally, dichloromethane was used. Results obtained for 
the aqueous extract of Chelidonii herba showed that only few phytochemical constituents 
were extracted. In order to save resources for microarray investigations, aqueous extracts 
were not included. For the same reason, extracts prepared with isopropanol were excluded 
as the study was not intended to match the regulatory background of Cimicifugae racemosae 
rhizoma. The correlation of the chemical profile to HepG2 cell proliferation showed that 
triterpene glycosides may be involved in antiproliferative effects. However, in accordance 
with previous studies, cinnamic acid esters are suggested to exhibit cytotoxic activities 
(Hostanska K., 2004a; Hostanska K., 2004b). The ethanolic and dichloromethane extract 
derived from Cimicifugae racemosae rhizoma exhibited the highest content of triterpene 
glycosides. Both herbal preparations exhibited a significant activation of several signal 
cascades associated with cholesterol biosynthesis and fatty acid metabolism. Less triterpene 
glycosides were demonstrated for the 50% (V/V) ethanolic extract containing Cimicifugae 
racemosae rhizoma. Cells exposed to the latter extract showed the induction of less signal 
cascades related to cholesterol biosynthesis and fatty acid metabolism. Hence, it may be 
suggested that triterpene glycosides might be responsible for cellular responses related to 
these signal cascades in our model. Similar results were obtained for signal cascades 
attributed to liver toxicity. The 50% (V/V) ethanolic Cimicifugae racemosae rhizoma extract 
did not affect liver-toxic signal cascades. Differences for extracts rich in triterpene glycoside 
were mainly displayed in signal cascades related to drug metabolism.  
In a third approach, a preparation containing Silybi mariani fructus and silybin, a chemically-
defined substance thereof with suggested pharmacological activity, were investigated. The 
objective was to identify altered genes and activated signal cascades in HepG2 cells of an 
herbal substance, which is not associated with liver toxicity. Moreover, experiments 
performed in this subproject specifically addressed the question in how far gene expression 
profiling can generate information to develop hypotheses on synergy and multitarget activity. 
Preparations containing Silybi mariani fructus are traditionally used for the treatment of liver 
diseases and furthermore, silymarin is approved for the treatment of Amanita phalloides 
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poisoning. A preparation containing Silybi mariani fructus was obtained using 70% (V/V) 
ethanol. Ethanol is often used for the preparation of finished herbal medicinal products 
containing Silybi mariani fructus.  
Microarray data analysis revealed that more and different signal cascades related to the 
biotransformation were altered for HepG2 cells after exposure to Silybi mariani fructus 
compared to the exposure to silybin. Commonly affected signal cascades identified for 
HepG2 cells after both treatments were liver damage and liver regeneration. However, 
results related to liver toxicity also showed differences, such as signal cascades associated 
with liver necrosis, exclusively activated after exposure to silybin; whereas the signal 
cascade “liver fibrosis” was exclusively induced after exposure to the 70% (V/V) ethanolic 
Silybi mariani fructus extract, respectively. These findings demonstrate that complex gene 
expression profiling technology can detect differences in cellular responses to an herbal 
preparation versus a chemically-defined substance. Moreover, significantly regulated genes 
associated with SLC transporters were identified. SLC transporters have been assigned to 
play a role in drug resistance (Januchowski R., 2013; Webb A., 2013). On the basis of gene 
expression profiling, the results demonstrate that a complex herbal preparation induced an 
entirely different mode of action compared to an individual chemically-defined substance 
thereof. Nevertheless, the question for genes responsible for the mode of action remains.  
Conclusively, the results obtained in the study on Chelidonii herba and Cimicifugae 
racemosae rhizoma with differently prepared herbal preparations indicated that a 
preparation-specific gene expression fingerprint was obtained. Moreover, the results 
obtained for Chelidonii herba and Cimicifugae racemosae rhizoma clearly underline the value 
of the existing concept of a clearly defined herbal substance and specifications for the 
manufacturing process to obtain consistently safe herbal medicinal products. Variations in 
the composition of herbal extracts may not only lead to toxic effects; interactions of drugs 
may also play a role in defining the safety of herbal medicinal products. On the basis of gene 
expression data, minor differences in the composition of constituents may result in a 
divergent regulation of cytochromes. These enzymes play a major role in drug metabolism. 
With regard to extracts representing different phytochemical constituents, different gene 
expression patterns were obtained, providing that preparation-specific gene expression 
signatures were obtained (fig. 32).  
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Fig. 32: Summary of activated (green) and unaffected (grey) signal cascades 
obtained with IPA microarray data evaluation. 1: ethanolic extract Chelidonii herba 
(58%), 2: ethanolic Cimicifugae racemosae rhizoma extract (61%), 3: 
dichloromethane Cimicifugae racemosae rhizoma extract (72%), 4: 50% (V/V) 
ethanolic Chelidonii herba extract (73%), 5: dichloromethane Chelidonii herba 
extract (77%), 6: 50% (V/V) ethanolic Cimicifugae racemosae rhizoma extract 
(81%), 7: 70% ethanolic Silybi mariani fructus extract (98%), 8: silybin (98%), 9: 
aqueous Chelidonii herba extract (105%). Values in brackets show relative cell 
proliferation of HepG2 cells after six hours of exposure to the extracts, 
respectively. 
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8.2 Validity of microarray data 
In the present study, microarray results were validated interlaboratorily by different 
experimenters using different microarray platforms. Identical RNA samples were 
investigated. Therefore, regarding biological variability it can be assumed that there is only a 
minor impact on variability of gene expression profiles. The coverage of genes with a less 
than threefold change was lower compared to genes with higher fold changes. The coverage 
of affected biological pathways showed increased congruency, another indicator of reliability 
of the data. Alternatively to a twofold change in gene expression, threefold changed genes 
could be used for the investigation of signal cascades. Regarding gene expression profiles in 
the present study, most genes showed smaller fold changes. Therefore, using threefold 
changed genes, a lot of information would have been ignored. Furthermore, qRT-PCR was 
used to validate selected genes. The results indicated good reliability, although minor 
differences in fold changes were observed. 
8.3 Gene expression profiling in the assessment of liver toxicity 
For the assessment of safety of herbal substances and herbal preparations clinical data are 
limited. The approach using gene expression profiling of HepG2 cells after exposure to 
different herbal preparations is a first step to increase knowledge, but concerning relevance 
in vivo, results have to be considered with caution. Concentration of the active substance in 
the herbal preparations used in cell culture experiments did not consider concentrations of 
herbal substances applied in therapy. Taken these limitations into account, the potential of 
gene expression profiling and systems biological data evaluation based on the performed 
experiments is roughly estimated for the use in the assessment of liver toxicity in the 
following paragraph.  
All signal cascades presented in this study were used for this evaluation, which showed most 
significant results with microarray data evaluation. However, other signal cascades were less 
significantly activated not shown in the present study.  
The correlation of antiproliferative effects and relative activated signal cascades and relative 
activated signal cascades related to toxicity indicates for most treatment conditions a 
correlation between antiproliferative effects and activated signal cascades (tab. 18). 
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Tab. 18 Antiproliferative effects in HepG2 cells and activation of signal cascades. Results of 
HepG2 cell proliferation were obtained after six hours of exposure of the different extracts. 
Activated signal cascades were set into relation to all activated signal cascades at least under 
one condition with respect to the respective experiment. Activated signal cascades related to 
toxicity were set into relation to all activated signal cascades associated with toxicity at least 
for one condition with respect to the respective experiment. 
 Antiproliferative 
effect of  
HepG2 cells 
Relative 
activated signal 
cascades (%) 
Relative activated 
signal cascades 
related to toxicity (%) 
C. majus ethanolic 
extract 
58 70.6 63.6 
C. racemosa ethanolic 
extract 
61 100.0 100.0 
C. racemosa 
dichloromethane 
extract 
72 90.5 100.0 
C. majus 50% (V/V) 
ethanolic extract 
73 58.8 54.6 
C. majus 
dichloromethane 
extract 
77 17.8 18.2 
C. racemosa 50% (V/V) 
ethanolic extract 
81 28.6 28.6 
S. marianum 70% 
ethanolic extract 
98 52.4 35.7 
Silybin 98 61.9 71.4 
C. majus aqueous 
extract 
105 5.9 0 
Extracts that provoked stronger antiproliferative effects in HepG2 cells activated a higher 
percentage of activated signal cascades. Regarding relatively activated signal cascades or 
relatively activated signal cascades related to toxicity, no major differences were identified. 
However, differences were observed in relative activated signal cascades of cells exposed to 
70% (V/V) ethanolic Silybi mariani fructus extract and silybin. For these two conditions no 
major antiproliferative effects were observed, even after prolonged exposure under both 
conditions. However, the number of activated signal cascades related to toxicities is quite 
high. These contrary results clearly underline that data obtained with gene expression 
profiling and systems biological data evaluation have to be regarded critically for biological 
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relevance. Nevertheless, in our model, effects may have been observed at the transcriptional 
level, which could not be elucidated with other methods. 
8.4 Current status of gene expression profiling: pros and cons 
The investigated gene expression profiling approach has shown the potential to be useful in 
the comprehensive characterization of herbal substances and preparations thereof.  
• The transcriptomics approach using microarray technique is very useful in the 
analysis of regulated genes. Specific gene expression “fingerprints” after exposure of 
HepG2 cells to herbal preparations were observed. 
 
• Regarding ethical considerations, in vitro studies better embrace animal protection 
and welfare than in vivo studies. Moreover, with regard to environmental influences, a 
well-characterized cell line may provide results with higher reproducibility. HepG2 
cells were shown to be a suitable model for the investigation of liver-toxic effects and 
they are frequently applied for toxicogenomics studies. HepG2 cells are of great 
relevance to detect cytotoxic and genotoxic substances and by extension 
cytoprotective, antigenotoxic and co-genotoxic agents (Mersch-Sundermann V., 
2004). In addition, HepG2 cells show metabolic activity represented by various 
biotransformation enzymes. For the characterization of herbal substances and their 
preparations, metabolic activity is an important characteristic. The metabolism of 
drugs and other xenobiotics is exemplified by cytochrome P450-mediated oxidation to 
more hydrophilic compounds. During biotransformation, some functional groups are 
oxidized, which can result in transient reactive intermediates. Phytochemical 
components, such as pyrrolizidine alkaloids require metabolic activation mediated by 
cytochrome P450 enzymes to generate reactive pyrrolic metabolites that react with 
cellular proteins and DNA leading to hepatotoxicity and genotoxicity (Fu P., 2004).  
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However, limitations of the transcriptomics-based have also been shown. 
• Statistical data evaluation has shown to have a large impact on the results obtained 
by microarray analysis. Recent publications with systems biological data evaluation 
selected genes with the lowest threshold of at least twofold change (Abd A., 2013; 
Filali H., 2014; Guo Y., 2013; Marshall A., 2013). However, in the current study, 
genes with threefold change showed higher congruency and reproducibility. Hence, 
the use of genes with a threefold increase may be more robust. The results of the 
present study represented rather low fold changes of gene expression. Only a few 
genes were significantly regulated tenfold or even higher. Therefore, also genes with 
a twofold expression were included for systems biology based data evaluation.  
 
• By using gene expression profiling, all experiments performed showed the activation 
of several signal cascades. On the level of gene expression data it is difficult to 
estimate signal cascades or networks responsible for the mode of action. Therefore, 
further investigations are necessary to clarify cellular responses. However, gene 
expression profiling may be beneficial to generate hypotheses for subsequent 
investigations.  
 
• The interpretation by systems biological approaches has to be considered carefully. 
Systems biology is an interdisciplinary science, using the combination of experimental 
procedure and (mathematical) models, which have contributed to the understanding 
of complex biological systems. But there is still an ongoing progress to unravel the 
association of gene regulation and protein formation; furthermore, systems biology-
based data evaluation is challenged by limited knowledge of the interplay of protein 
networks and the large number of regulatory feedback loops (Draghici S., 2007; 
Kaltenbach H., 2009; Klipp E., 2009; Maier T., 2009; Savageau M., 2009). By 
identifying activated signal cascades only the set of gene is considered, the position 
yet is ignored (Draghici S., 2007).  
 
• In the present study, HepG2 cells have shown limitations for the functional 
characterization of the investigated herbal substances and their preparations. For 
silymarin it was previously shown that SLC transporters (SLC21A6) may be involved 
in the proposed toxin blockade (Fehrenbach T., 2003). The SLC21A6 protein has not 
been identified in HepG2 cells (Cui Y., 2003). Furthermore, HepG2 cells lack 
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estrogen receptor α (ERα), therefore postulated estrogenic effects of Cimicifugae 
racemosae rhizoma could not be investigated.  
 
• Results obtained by in vitro methods and microarrays should be considered with 
caution for relevance in vivo. By using in vitro technologies, important issues can be 
addressed, such as the activation of (specific) biotransformation enzymes 
(Masimirembwa, 2001). However, currently, in vivo methods can not be fully replaced.  
8.5 Outlook: Combined approach bridging of data about the chemical profile 
and the functional activity 
The approach of the combined investigation of the chemical profile and the functional 
characterizations by gene expression profiling seems to be very promising. Current findings 
obtained in the present study established a basis for further studies.  
Mixtures of complex herbal substances and herbal preparations are frequently applied. 
Therefore, regarding gene expression profiling experiments, it would be highly interesting to 
investigate putative synergistic effects of such mixtures.  
As an extension of the approach investigated, additional analysis of the proteome would offer 
the opportunity to further investigate cells exposed to herbal substances and herbal 
preparations. 
8.6 Metabolomic fingerprinting 
In previous research projects of the BfArM, an approach related to metabolomics was 
investigated for its future potential in regulatory affairs (Daniel C., 2009). The approach 
targeted on the authentication of herbal substances. In this study, the approach was further 
tested on applicability, possibilities and limitations in the investigation of herbal substances 
related to Asian therapeutic system.  
In an earlier study, three different species of the genus Artemisia were investigated (Daniel 
C., 2009). In the present study, data were re-evaluated and clustering results were obtained. 
In cooperation with Prof. Heilmann from the University of Regensburg, 18 A. scoparia 
samples from different provenances were investigated additionally, also displaying clusters in 
PCA. The potential of this technique was clearly shown, as discriminating groups of 
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constituents were shown to be identical by the metabolomics-based approach and standard 
methods.  
8.7 Potential of metabolomics-based approach 
According to the results achieved in this study, the importance of marker substances in 
assessment of herbal preparations should be reconsidered. But investigations of the present 
study with differently prepared Chelidonii herba extracts showed that potential toxic 
components like alkaloids were not involved in the classification of herbal preparations. 
Therefore, the metabolomics-based approach cannot be used to completely substitute 
standard methods that quantify toxicity-related herbal compounds. For the appropriate 
authentication of herbal substances with 1H-NMR analysis in combination with PCA, a 
database with an adequate number of samples has to be constructed. 
8.8 PCR-based approach 
Regarding the identification of herbal substances, sequence data from three different 
Artemisia sp. obtained in a previous study in our group were re-evaluated (Daniel C., 2009). 
The results of the PCR-based approach using ITS-sequencing are summarized (tab. 19). 
Tab. 19: Summary of results obtained for different Artemisia sp. with the PCR-based method. 
 A. argyi A. annua A. scoparia 
DNA extraction    
PCR    
Sequencing results    
Species identification by NCBI BLAST 
database 
   
The herbal material investigated was dried but unprocessed. The extraction of DNA and 
subsequent PCR with universal plant specific primers established in the research project 
(Kersten T., 2013) were successful for all samples analyzed. The resulting PCR-fragments 
were sequenced successfully and results showed species-specific homologies. For A. argyi 
112 
and A. annua, the herbal origin was clearly identified by evaluation of the obtained ITS-
sequences. The results obtained for A. scoparia ITS sequences corresponded mostly to 
Artemisia sp, a sequencing result provided to the NCBI database by C. Daniel and W. Knöß 
in a former research project. By retracing of the sequencing results, A. scoparia was 
identified as the plant origin. The sequencing results of the PCR-fragment obtained from one 
A. scoparia sample showed minor differences in the sequence, although no major 
morphological differences could be identified. The 1H-NMR analysis and subsequent PCA did 
not demonstrate major differences. According to the NCBI BLAST alignment, differences in 
the sequence led to a divergent classification of the herbal origin. Hence, the identification of 
herbal origin was ensured by the usage of a second marker region using ETS sequence. 
8.9 Potential of marker regions to identify herbal substances 
Basically, the PCR-based approach is a suitable method to identify herbal substances. The 
investigation of one marker region showed to be valuable as a simple method for a first 
orientation. At least two herbal marker regions should be recruited to obtain reliable results, 
which display statements of current reports on the literature (Erickson D., 2008; CBOL Plant 
Working Group, 2009). For future prospects, a second universal marker region should be 
established to unambiguously identify herbal substances. 
Furthermore, the results of NCBI database should be obtained carefully. As it is an open 
access database, the reliability of sequences has to be considered carefully. According to the 
number of reference data available, ITS seems to be a powerful marker region (tab. 20). In 
the future, collection of reliable sequences from marker regions of medicinal plants should be 
continued. 
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Tab. 20: Number of entities of DNA sequences for land plants in the database NCBI 
(www.ncbi.nlm.nih.gov; 10. 2. 2014). Multiple entries for the identical plant are possible for the 
marker sequence, respectively. 
Marker Entries for land plants 
ITS 175,843 
ETS 19,048 
matK 95,060 
rbcL 107,437 
psbA 64,298 
trnH 61,423 
Cox1 1,225 
A combined approach, using the 1H-NMR fingerprints together with the analysis of marker 
substances is of great interest for a first characterization of herbal substances and herbal 
preparations. Investigations showed that Artemisia sp. was a good example for the 
characterization by these complementary methods; hence, it may be suggested that this 
combined approach is useful in the characterization of the herbal substances derived from 
the genus Artemisia. PCA is promising in the analysis of quality of herbal preparations and 
the application of marker substances is valuable for identification.  
The present study indicated that standard methods can be complemented by recently 
developed methods. Gene expression profiling in combination with the metabolomics-based 
approach may be beneficial for the assessment of quality, analysis of global gene response 
and the identification of putative mechanisms of action. Metabolomics-based approaches are 
highly valuable for the classification of multicomponent mixtures as results obtained in the 
present study clearly show. The application of marker substances was proven to be suitable 
for retracing of the origin of herbal substances. In summary, new methodologies are suitable 
to contribute to characterize herbal substances and herbal preparations; however, current 
knowledge is limited and further studies are needed to consider routine application with 
respect to regulatory affairs. 
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9 Summary 
Herbal substances and preparations thereof have been applied and used worldwide 
throughout human history. Regarding regulatory affairs, the assessment of quality of herbal 
substances and their preparations is mandatory. Quality control is challenging, as herbal 
substances and their preparations are always complex mixtures. Furthermore, herbal 
substances and their preparations are suggested to act on multiple targets; therefore, a 
comprehensive characterization of biological function is of major impact. 
The focus of the present thesis was to bridge data about the chemical profile and the 
biological activity of herbal preparations (fig. 33).  
 
Fig. 33: Strategy for the characterization of herbal preparations. 
Recently emerging omics-techniques have been shown to be useful in the characterization of 
herbal substances and their preparations. Regarding quality of complex mixtures comprising 
various phytochemical constituents, 1H-NMR analysis in combination with principal 
component analysis (PCA) is a highly valuable approach. In the present study, different 
herbal preparations were chemically characterized by their metabolome. Additionally, 
standard methods of the European Pharmacopeia were applied for the quantification of 
selected marker compounds. With respect to characterization of biological activities, a 
transcriptomics-based approach was used. HepG2 cells were exposed to different herbal 
preparations and gene expression profiling was used to comprehensively characterize global 
cellular responses. Cell proliferation after exposure to different extracts was investigated. 
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Cellular effects were characterized by gene expression profiling and by systems biological 
data evaluation; regulated genes were attributed to affected signal cascades. Selected 
differently regulated genes were verified by qRT-PCR.  
In the present study, three different herbal substances and one isolated constituent thereof 
were comprehensively investigated. For Chelidonii herba and Cimicifugae racemosae 
rhizoma several cases associated with liver toxicities have been reported. Herbal 
preparations with different patterns of phytochemical components were obtained by 
extraction with solvents of different polarities. The third herbal substance, Silybi mariani 
fructus, has traditionally been used for treatment of diseases related to liver and gallbladder.  
The results of the investigations with different extracts containing Chelidonii herba 
demonstrated that the extraction solvent used had an impact on the composition of 
constituents. These differences could be discriminated by PCA. Standard methods showed 
characteristic patterns of alkaloids for the different extracts. Differences in the composition of 
herbal constituents also provoked different antiproliferative effects on HepG2 cells. The 
ethanolic extract marked the strongest antiproliferative effects. By correlating these results to 
the chemical profile it could be suggested that the total alkaloid content may not exclusively 
be responsible for liver toxicity. Systems biological data evaluation showed that most 
significantly induced signal cascades associated with liver toxicity were identified for HepG2 
cells exposed to the ethanolic extract. Moreover, differences in cellular responses were 
mainly associated with drug metabolism.  
Three herbal preparations derived from Cimicifugae racemosae rhizoma could be clearly 
discriminated by PCA of 1H-NMR fingerprinting. Quantification of triterpene glycosides 
revealed varying contents thereof in the extracts. The ethanolic extract represented the 
highest amount of triterpene glycosides and provoked highest antiproliferative effects on 
HepG2 cells. The content of triterpene glycosides bridged to HepG2 cell proliferation could 
lead to the hypothesis that these phytochemical constituents were mainly responsible for 
antiproliferative effects in the used model. Moreover, as demonstrated by microarray 
experiments a high number of affected signal cascades were related to liver toxicity, e. g. 
liver necrosis and cell death were identified for extracts containing high amounts of triterpene 
glycosides such as the ethanolic and the dichloromethane Cimicifugae racemosae rhizoma 
extract. Additionally, a higher number of significantly activated signal cascades associated 
with cholesterol biosynthesis and lipid metabolism were identified for preparations derived 
from Cimicifugae racemosae rhizoma representing high contents of triterpene glycosides. 
Differences in signal cascades related to biotransformation were identified for HepG2 cells 
after exposure to herbal preparations showing a similar content of triterpene glycosides. 
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Hence, this may lead to the suggestion that various groups of phytochemical constituents are 
involved in activation of genes related to drug metabolism. 
For Silybi mariani fructus, investigation was focusing on applying the methodology on an 
herbal preparation and on silybin, a defined natural constituent of this preparation. 1H-NMR 
fingerprinting indicated a characteristic pattern of various phytochemical constituents in the 
herbal preparation. Silymarin was quantified using standard methods. HepG2 cells were 
either exposed to this herbal preparation or to silybin in similar concentrations related to 
silymarin. Cell proliferation was rather not affected after exposure to both treatment 
conditions. Gene expression profiles revealed major differences affecting signal cascades 
related to toxicity, which were more frequently induced in HepG2 cells after exposure to 
silybin. Signal cascades related to biotransformation were differentially activated. 
Additionally, regulated genes were identified which are suggested to play a role in drug 
resistance.  
The reproducibility of the methodology using microarrays was investigated. Identical RNA 
samples were investigated by different microarray platforms in our laboratory and by a 
company which commercially provides microarray services. Highest variability of the data 
was identified for significantly regulated genes with low fold changes. A higher congruency 
was obtained for at least threefold regulated genes. This comparison indicated differences in 
the gene expression profiles; however, a higher correlation of affected signal cascades was 
shown. Various studies apply genes with significant twofold regulated genes for microarray 
data evaluation, although reproducibility of gene expression improves with threefold change. 
In the present study, at least twofold significantly regulated genes were included to follow the 
strategy frequently applied in microarray experiments; moreover, in the present study, only a 
limited amount of genes represented high fold changes. 
A subproject of this thesis evaluated in detail the potential of the metabolomics-based 
method and a polymerase chain reaction (PCR)-based approach, applied for the 
identification of herbal substances. This subproject based on methods previously established 
in our group. Investigations of Artemisia scoparia Waldst. & Kit. samples were performed in 
cooperation (Prof. Heilmann and Prof. Franz from the University of Regensburg) to directly 
compare data about the chemical profile by standard methods and the metabolomics-based 
approach. For this purpose, A. scoparia samples from different provenances (China and 
Germany) were investigated. Using the metabolomics-based approach together with PCA, 
discrimination of Artemisia sp. was obtained. Regarding phytochemical groups of 
constituents responsible for the classification, mainly terpenoids, but also phenolics, 
flavonoids and phenylpropanoids were identified. Standard methods revealed that terpenoids 
(essential oil) and flavonoids widely varied between the herbal samples from different 
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provenances. Thereby, it was clearly shown that the metabolomics-based approach is highly 
valuable for a global classification of herbal preparations. Furthermore, the potential of this 
approach was positively evaluated as classification of different Artemisia sp., monographed 
in the Chinese Pharmacopeia, could be achieved at the species level. The analysis of at 
least two marker sequences is recommended to unambiguously identify the herbal origin. 
The comprehensive characterization of complex herbal mixtures by a metabolome-based 
approach is very useful for authentication of herbal substances and reliable for the 
discrimination of major constituents. However, regarding phytochemical metabolites present 
in small amounts, limitations of the method were shown. For the identification of herbal 
substances, the PCR-based approach by ITS sequencing is suitable.  
The present thesis provided new insights by bridging data about the chemical profile and 
gene expression profiles of herbal preparations. The investigation and correlation of both the 
chemical profile and functional activities is promising to comprehensively characterize herbal 
substances and their preparations. Regarding specificity, the metabolomics-based approach 
and gene expression profiling clearly showed characteristic signatures depending on the 
herbal preparation used. These results show the high importance of a defined manufacturing 
procedure. However, knowledge in gene regulation and systems biology is still limited and 
data about signal cascades affected in an in vitro system are only a starting point for further 
investigations. 
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